Gene Variant Detail

Filtering

Case insensitive filtering will display rows if any text in any cell matches the filter term
Use simple literal full or partial string matches
Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
Click on any column header arrows to sort by that column
Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Clinical Trial	Phase	Therapies	Title	Recruitment Status	Covered Countries	Other Countries
NCT01784640	Phase I	Luminespib + Pemetrexed Disodium	Pemetrexed Disodium and Hsp90 Inhibitor AUY922 in Treating Patients With Previously Treated Stage IV Non-Small Cell Lung Cancer	Completed	USA	0
NCT04591431	Phase II	Everolimus Nivolumab Itacitinib Erlotinib Ponatinib Pemigatinib Ipatasertib Ipilimumab Cobimetinib Atezolizumab Palbociclib Entrectinib Vemurafenib Lapatinib Trastuzumab Brigatinib Alectinib Ado-trastuzumab emtansine Pertuzumab Vismodegib	The Rome Trial From Histology to Target: the Road to Personalize Target Therapy and Immunotherapy (ROME)	Active, not recruiting	ITA	0
NCT06357533	Phase III	Pembrolizumab AZD2936 + Datopotamab deruxtecan AZD2936	Phase III, Open-label, Study of First-line Dato-DXd in Combination With Rilvegostomig for Advanced Non-squamous NSCLC With High PD-L1 Expression (TC >= 50%) and Without Actionable Genomic Alterations (TROPION-Lung10)	Recruiting	USA \| TUR \| POL \| ITA \| HUN \| GBR \| ESP \| DEU \| CAN \| BRA \| BEL \| AUT \| AUS	6
NCT03345810	Phase II	Gemcitabine + Vinorelbine Carboplatin + Nab-paclitaxel Carboplatin + Durvalumab + Nab-paclitaxel Durvalumab + Gemcitabine + Vinorelbine	Durvalumab (MEDI4736) in Frail and Elder Patients With Metastatic NSCLC (DURATION) (DURATION)	Completed	DEU	0
NCT02091141	Phase II	Erlotinib Alectinib Cobimetinib + Vemurafenib Pertuzumab + Trastuzumab Vismodegib Atezolizumab	My Pathway: A Study Evaluating Herceptin/Perjeta, Tarceva, Zelboraf/Cotellic, Erivedge, Alecensa, and Tecentriq Treatment Targeted Against Certain Molecular Alterations in Participants With Advanced Solid Tumors	Completed	USA	0
NCT05541822	Phase II	ABN401	To Evaluate the Efficacy, Safety, Tolerability and Pharmacokinetic Profile of ABN401 in Patients With Advanced Solid Tumors Harboring c-MET Dysregulation	Recruiting	USA	2
NCT03975114	Phase II	Durvalumab + Tremelimumab Durvalumab	A Study Comparing Immunotherapy With Chemotherapy in the Treatment of Elderly Patients With Advanced NSCLC (MILES-5) (MILES-5)	Recruiting	ITA	0
NCT03515629	Phase III	Cemiplimab + Ipilimumab Pembrolizumab	REGN2810 (Anti-PD-1 Antibody), Platinum-based Doublet Chemotherapy, and Ipilimumab (Anti-CTLA-4 Antibody) Versus Pembrolizumab Monotherapy in Patients With Lung Cancer	Terminated	USA \| LTU \| ITA	0
NCT05493566	Phase I	Aldesleukin + Pembrolizumab	Low-Dose Interleukin-2 and Pembrolizumab for the Treatment of Stage IV Non-Small Cell Lung Cancer	Recruiting	USA	0
NCT06120075	Phase I	AB801 AB801 + Docetaxel AB801 + Docetaxel + Zimberelimab	A Study of AB801 Monotherapy and Combination Therapy in Participants With Advanced Malignancies (ARC-27)	Recruiting	USA	0
NCT05746481	Phase II	Atezolizumab + Carboplatin + Pemetrexed Disodium + Tiragolumab	Carboplatin, Pemetrexed, and Atezolizumab in Patients With Non-squamous Non-small Cell Lung Cancer (NSCLC) and Untreated Brain Metastases	Recruiting	USA	0
NCT02495636	Phase II	Atezolizumab + Rasdegafusp alfa	Phase 2 Study of MPDL3280A Combined With CDX-1401 in NY-ESO 1 (+) IIIB, IV or Recurrent Non-Small Cell Lung Cancer	Withdrawn	USA	0
NCT05987644	Phase Ib/II	Alectinib	Delayed or Upfront Brain RAdiotherapy in Treatment naive Lung Cancer Patients With Asymptomatic or Minimally Symptomatic Brain Metastases and ALK rEarrangements (DURABLE)	Recruiting	USA	0
NCT04341181	Phase II	Atezolizumab Niraparib Erlotinib Axitinib Cobimetinib + Vemurafenib Avelumab Pertuzumab + Trastuzumab Vismodegib Alectinib Ado-trastuzumab emtansine	ProTarget - A Danish Nationwide Clinical Trial on Targeted Cancer Treatment Based on Genomic Profiling (ProTarget)	Recruiting	DNK	0
NCT04116541	Phase II	Alectinib Cabozantinib Ribociclib + Siremadlin	A Study Evaluating the Activity of Anti-cancer Treatments Targeting Tumor Molecular Alterations/Characteristics in Advanced / Metastatic Tumors. (MegaMOST)	Recruiting	FRA	0
NCT04198766	Phase I	INBRX-106 INBRX-106 + Pembrolizumab	Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)	Recruiting	USA	0
NCT04013542	Phase I	Ipilimumab + Nivolumab Nivolumab	Ipilimumab and Nivolumab in Combination With Radiation Therapy in Treating Patients With Stage 2-3 Non-small Lung Cancer	Active, not recruiting	USA	0
NCT03993873	Phase Ib/II	Elzovantinib	Study of TPX-0022 in Patients With Advanced NSCLC, Gastric Cancer or Solid Tumors Harboring Genetic Alterations in MET (SHIELD-1)	Active, not recruiting	USA \| FRA \| ESP	1
NCT03703050	Phase II	Nivolumab	Nivolumab for Pediatric and Adult Relapsing/Refractory ALK+, for Evaluation of Response in Patients With Progressive Disease (Cohort 1) or as Consolidative Immunotherapy in Patients in Complete Remission After Relapse (Cohort 2) (NIVO-ALCL)	Recruiting	NLD \| FRA \| DNK	0
NCT04585477	Phase II	Durvalumab	Adjuvant ctDNA-Adapted Personalized Treatment in Early Stage NSCLC (ADAPT-E)	Recruiting	USA	0
NCT03647488	Phase II	Capmatinib + Spartalizumab Docetaxel	Study of Capmatinib and Spartalizumab Combination Therapy vs Docetaxel in Non-small Cell Lung Cancer	Completed	USA \| ISR \| FRA \| ESP \| DEU \| BEL	0
NCT05077709	Phase II	IO102-IO103 + Pembrolizumab	IO102-IO103 in Combination With Pembrolizumab as First-line Treatment for Patients With Metastatic NSCLC, SCCHN, or mUBC	Active, not recruiting	USA \| GBR \| ESP	0
NCT04427072	Phase III	Docetaxel Capmatinib	Study of Capmatinib Efficacy in Comparison With Docetaxel in Previously Treated Participants With Non-small Cell Lung Cancer Harboring MET Exon 14 Skipping Mutation (GeoMETry-III)	Completed	NLD \| ITA \| FRA \| ESP \| DEU \| BRA \| BEL	3
NCT03178071	Expanded access	Lorlatinib	Expanded Access For Lorlatinib For Patients With Non Small Cell Lung Cancer Harboring Specific Molecular Alterations	No longer available	USA	0
NCT06094296	Phase II	Cisplatin + Nivolumab + Pemetrexed Disodium BMS-986315 + Cisplatin + Nivolumab + Pemetrexed Disodium BMS-986315 + Carboplatin + Nivolumab + Pemetrexed Disodium BMS-986315 + Carboplatin + Nivolumab + Paclitaxel Carboplatin + Nivolumab + Pemetrexed Disodium Carboplatin + Nivolumab + Paclitaxel	A Study of BMS-986315 and Nivolumab in Combination With Chemotherapy in Participants With First-line Stage IV or Recurrent Non-small Cell Lung Cancer (NSCLC)	Completed	USA \| AUS	0
NCT01772004	Phase I	Avelumab	Avelumab in Metastatic or Locally Advanced Solid Tumors (JAVELIN Solid Tumor)	Completed	USA \| POL \| GBR \| FRA \| DEU \| CZE \| BEL	2
NCT03611738	Phase I	Ceritinib + Docetaxel	Ceritinib Plus Docetaxel in ALK-Negative, EGFR WT Advanced NSCLC	Active, not recruiting	USA	0
NCT04105270	Phase II	Carboplatin + Durvalumab + Pemetrexed Disodium Cisplatin + Durvalumab + Pemetrexed Disodium	RMT in Combination With Durvalumab + Chemo in Untreated Adenocarcinoma NSCLC. A Randomized Double Blind Phase II Trial	Recruiting	USA	0
NCT02395172	Phase III	Avelumab Docetaxel	Avelumab in Non-Small Cell Lung Cancer (JAVELIN Lung 200)	Completed	USA \| TUR \| SVK \| ROU \| POL \| ITA \| ISR \| HUN \| HRV \| GBR \| FRA \| ESP \| DNK \| CZE \| CHE \| BRA \| BGR \| BEL \| AUS \| ARG	9
NCT04800822	Phase I	PF-07284892 Cetuximab + Encorafenib + PF-07284892 Lorlatinib + PF-07284892 Binimetinib + PF-07284892	PF-07284892 in Participants With Advanced Solid Tumors	Terminated	USA	0
NCT02879617	Phase II	Durvalumab	A Clinical Trial of Durvalumab (MEDI4736) as 1st Line Therapy in Advanced Non-small Cell Lung Cancer Patients	Completed	USA	0
NCT05800015	Phase II	Cemiplimab + Cisplatin + Fianlimab + Pemetrexed Disodium Carboplatin + Cemiplimab + Fianlimab + Paclitaxel Cemiplimab + Cisplatin + Paclitaxel Carboplatin + Cemiplimab + Paclitaxel	A Trial to Learn How the Combination of Fianlimab With Cemiplimab and Chemotherapy Works Compared With Cemiplimab and Chemotherapy for Treating Adult Patients With Advanced Non-small Cell Lung Cancer	Recruiting	USA \| ISR \| CAN \| AUS	4
NCT06364917	Phase II	Carboplatin + Pembrolizumab + Pemetrexed Disodium Pembrolizumab + Pemetrexed Disodium Ipilimumab + Nivolumab Carboplatin + Ipilimumab + Nivolumab + Paclitaxel Carboplatin + Ipilimumab + Nivolumab + Pemetrexed Disodium Carboplatin + Paclitaxel + Pembrolizumab	DISCERN: Dual Versus Single ICB in PDL-1 Negative NSCLC	Not yet recruiting	USA	0
NCT03409614	Phase III	Cemiplimab + Ipilimumab Cemiplimab	Combinations of Cemiplimab (Anti-PD-1 Antibody) and Platinum-based Doublet Chemotherapy in Patients With Lung Cancer	Active, not recruiting	USA \| TUR \| SVK \| ROU \| POL \| LTU \| ITA \| IRL \| GRC \| FRA \| AUT	7
NCT02578680	Phase III	Carboplatin + Pemetrexed Disodium Carboplatin + Pembrolizumab + Pemetrexed Disodium Cisplatin + Pembrolizumab + Pemetrexed Disodium Cisplatin + Pemetrexed Disodium	Study of Pemetrexed+Platinum Chemotherapy With or Without Pembrolizumab (MK-3475) in Participants With First Line Metastatic Nonsquamous Non-small Cell Lung Cancer (MK-3475-189/KEYNOTE-189)	Completed		0
NCT01935336	Phase II	Ponatinib	Study of Ponatinib in Patients With Lung Cancer Preselected Using Different Candidate Predictive Biomarkers	Completed	USA	0
NCT03322540	Phase II	Pembrolizumab Epacadostat + Pembrolizumab	Pembrolizumab Plus Epacadostat vs Pembrolizumab Plus Placebo in Metastatic Non-Small Cell Lung Cancer (KEYNOTE-654-05/ECHO-305-05)	Completed	USA \| TUR \| POL \| ITA \| ISR \| IRL \| GBR \| EST \| ESP \| DNK \| CHE \| CAN \| AUS	5
NCT02013219	Phase I	Alectinib + Atezolizumab Atezolizumab + Erlotinib	A Phase 1b Study of Atezolizumab in Combination With Erlotinib or Alectinib in Participants With Non-Small Cell Lung Cancer	Completed	USA \| GBR \| FRA \| ESP	2
NCT05770037	Phase II	Alectinib	DETERMINE Trial Treatment Arm 01: Alectinib in Adult, Teenage/Young Adults (TYA) and Paediatric Patients With ALK Positive Cancers (DETERMINE)	Recruiting	GBR	0
NCT01121588	Phase I	Crizotinib	An Investigational Drug, Crizotinib (PF-02341066), Is Being Studied In Tumors, Except Non-Small Cell Lung Cancer, That Are Positive For Anaplastic Lymphoma Kinase (ALK)	Terminated	USA \| ITA	5
NCT02277457	Phase I	Crizotinib Erlotinib	Personalized Adaptive Radiation Therapy With Individualized Systemic Targeted Therapy (PARTIST) for Locally Advanced, Non-small Cell Lung Cancer With Genomic Driver Mutations	Withdrawn	USA	0
NCT03175224	Phase Ib/II	Vebreltinib	APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors (SPARTA)	Recruiting	USA \| ITA \| HUN \| GBR \| FRA \| FIN \| ESP \| CAN \| AUS	4
NCT05501665	Phase Ib/II	Carboplatin + Pembrolizumab + Pemetrexed Disodium Carboplatin + Nab-paclitaxel + Pembrolizumab	Split Course Adaptive Radiation Therapy With Pembrolizumab With/Without Chemotherapy for Treating Stage IV Lung Cancer	Recruiting	USA	0
NCT05311709	Phase II	Sotorasib	Sotorasib in Advanced KRASG12C-mutated Non-small Cell Lung Cancer Patients With Comorbidities (SOLUCOM)	Recruiting	NOR	0
NCT05397171	Phase Ib/II	AZD8853	A First-in-human Study to Evaluate the Safety and Tolerability of AZD8853 in Participants With Selected Advanced/Metastatic Solid Tumours	Terminated	USA \| CAN	0
NCT05925530	Phase II	Durvalumab	Study to Assess Neoadjuvant Durvalumab (D) and Platinum-Based Chemotherapy (CT), Followed by Either Surgery and Adjuvant D or CRT and Consolidation D, in Resectable or Borderline Resectable Stage IIB-IIIB NSCLC (MDT-BRIDGE) (MDT-BRIDGE)	Recruiting	USA \| SWE \| ITA \| HUN \| FRA \| ESP \| DEU \| CZE \| CAN \| AUT	1
NCT06627647	Phase III	AZD2936 + Pemetrexed Disodium Cisplatin + Pembrolizumab + Pemetrexed Disodium AZD2936 + Carboplatin + Pemetrexed Disodium AZD2936 + Cisplatin + Pemetrexed Disodium Pembrolizumab + Pemetrexed Disodium Carboplatin + Pembrolizumab + Pemetrexed Disodium	A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Metastatic Non-squamous NSCLC	Not yet recruiting	USA \| TUR \| HUN \| GBR \| ESP \| DEU \| CAN \| BRA \| BEL \| ARG	7
NCT02259114	Phase I	Birabresib	A Phase IB Trial With OTX015, a Small Molecule Inhibitor of the Bromodomain and Extra-Terminal (BET) Proteins, in Patients With Selected Advanced Solid Tumors	Completed		0
NCT03505554	Phase II	Lorlatinib	A Study of Oral Lorlatinib in Patients With Relapsed ALK Positive Lymphoma (CRU3)	Recruiting	ITA	0
NCT02336451	Phase II	Ceritinib	A Phase II Study to Evaluate the Efficacy and Safety of Oral Ceritinib in Patients With ALK-positive NSCLC Metastatic to the Brain and/or to Leptomeninges	Completed	USA \| TUR \| NLD \| ITA \| GBR \| FRA \| ESP \| DEU \| CAN \| BRA \| BEL \| AUS	5
NCT05401786	Phase II	Cemiplimab Ipilimumab	Anti-PD-1 Re-challenge After Immune Priming by Ipilimumab and Immune Boosting by Radiotherapy in Advanced NSCLC (RAD-IO)	Recruiting	NLD	0
NCT05589818	Phase II	Pembrolizumab	Pembrolizumab for Advanced NSCLC and PS 2-3	Recruiting	USA	0
NCT04634110	Phase II	Brigatinib	Brigatinib Before Brain Irradiation Trial (B3i Trial)	Terminated	USA	0
NCT03696212	Phase Ib/II	Grapiprant + Pembrolizumab	Grapiprant (ARY-007) and Pembrolizumab in Patients With Advanced or Metastatic Post-PD-1/L1 NSCLC Adenocarcinoma	Terminated	USA	0
NCT05445843	Phase II	JDQ443	Study of Efficacy and Safety of JDQ443 Single-agent as First-line Treatment for Patients With Locally Advanced or Metastatic KRAS G12C- Mutated Non-small Cell Lung Cancer With a PD-L1 Expression < 1% or a PD-L1 Expression >= 1% and an STK11 Co-mutation.	Active, not recruiting	USA \| TUR \| NLD \| ITA \| HUN \| GRC \| GBR \| FRA \| ESP \| DEU \| BRA \| BEL \| AUT \| ARG	5
NCT06088771	Phase Ib/II	Cemiplimab + Dupilumab	Neoadjuvant Dupilumab and Cemiplimab in Patients With Early-stage Resectable NSCLC	Recruiting	USA	0
NCT02393625	Phase I	Ceritinib + Nivolumab	Study of Safety and Efficacy of Ceritinib in Combination With Nivolumab in Patients With ALK-positive Non-small Cell Lung Cancer	Active, not recruiting	USA \| ITA \| ESP \| CAN \| BEL \| AUS	2
NCT05384626	Phase Ib/II	NVL-655	A Study of NVL-655 in Patients With Advanced NSCLC and Other Solid Tumors Harboring ALK Rearrangement or Activating ALK Mutation (ALKOVE-1)	Recruiting	USA \| NLD \| ITA \| GBR \| FRA \| ESP \| DEU \| CHE \| CAN \| BEL \| AUS	4
NCT02231164	Phase III	Docetaxel Nintedanib	LUME-Columbus: Nintedanib Plus Docetaxel in Advanced Non-small Cell Lung Cancer With Translational Research	Terminated	USA	2
NCT04940637	Phase II	Dostarlimab-gxly + Niraparib	UNITO-001- Study in HRR/PDL1 Positive MPM/NSCLC (UNITO-001)	Recruiting	ITA	0
NCT04693468	Phase I	Axitinib + Talazoparib Crizotinib + Talazoparib Palbociclib + Talazoparib	Talazoparib and Palbociclib, Axitinib, or Crizotinib for the Treatment of Advanced or Metastatic Solid Tumors, TalaCom Trial	Recruiting	USA	0
NCT02451865	Phase I	Binimetinib + Docetaxel	Binimetinib With Docetaxel in Treating Patients With Previously Treated, Stage IV Non-small Cell Lung Cancer	Withdrawn	USA	0
NCT03996473	Phase Ib/II	Pembrolizumab Pembrolizumab + Radium Ra 223 dichloride	Study to Test the Safety and How Radium-223 Dichloride an Alpha Particle-emitting Radioactive Agent Works in Combination With Pembrolizumab an Immune Checkpoint Inhibitor in Patients With Stage IV Non-small Cell Lung Cancer With Bone Metastases	Terminated	USA \| NLD \| ESP \| BEL	0
NCT05005273	Phase II	Ipilimumab + Nivolumab BMS-986207 + Ipilimumab + Nivolumab	A Study to Assess BMS-986207 in Combination With Nivolumab and Ipilimumab as First-line Treatment for Participants With Stage IV Non-Small Cell Lung Cancer	Completed	USA \| TUR \| POL \| ITA \| ISR \| FRA \| ESP \| DEU \| BEL \| AUS \| ARG	1
NCT02041533	Phase III	Nivolumab Paclitaxel Cisplatin Pemetrexed Disodium Carboplatin Gemcitabine	An Open-Label, Randomized, Phase 3 Trial of Nivolumab Versus Investigator's Choice Chemotherapy as First-Line Therapy for Stage IV or Recurrent PD-L1+ Non-Small Cell Lung Cancer (CheckMate 026)	Completed	USA \| TUR \| SWE \| ROU \| POL \| NLD \| ITA \| HUN \| GRC \| GBR \| FRA \| FIN \| ESP \| DEU \| CZE \| CHE \| CAN \| BRA \| BEL \| AUT \| AUS \| ARG	4
NCT05689671	FDA approved	Cisplatin + Pembrolizumab + Pemetrexed Disodium Carboplatin + Pembrolizumab + Pemetrexed Disodium Atezolizumab + Carboplatin + Nab-paclitaxel	Pemetrexed-free vs. Pemetrexed-based Immunochemotherapy in Metastatic TTF-1 Negative Lung Adenocarcinoma (ANTELOPE)	Recruiting	DEU	0
NCT05469178	Phase Ib/II	Bemcentinib + Carboplatin + Pembrolizumab + Pemetrexed Disodium	A Study to Investigate the Safety, Tolerability, and Preliminary Anti-tumor Activity of Bemcentinib in Combination With Pembrolizumab Plus Pemetrexed and Carboplatin in Adult Participants With Untreated Non-squamous Non-small Cell Lung Cancer	Recruiting	USA	0
NCT04929041	Phase II	Pembrolizumab Nab-paclitaxel Ipilimumab Paclitaxel Nivolumab Pemetrexed Disodium Carboplatin	Testing the Addition of Radiation Therapy to Immunotherapy for Stage IV Non-Small Cell Lung Cancer Patients Who Are PD-L1 Negative	Recruiting	USA	0
NCT04270591	Phase Ib/II	SCC244	Assessment of Anti-tumor and Safety in Glumetinib in Patients With c-MET-positive Non-Small Cell Lung Cancer	Recruiting	USA	2
NCT04632992	Phase II	Ipatasertib Atezolizumab + Capecitabine Entrectinib Atezolizumab + Docetaxel Ado-trastuzumab emtansine + Atezolizumab Capecitabine + Pertuzumab/trastuzumab/hyaluronidase-zzxf Paclitaxel + Pertuzumab/trastuzumab/hyaluronidase-zzxf Alectinib Inavolisib Pertuzumab/trastuzumab/hyaluronidase-zzxf Docetaxel + Pertuzumab/trastuzumab/hyaluronidase-zzxf Atezolizumab + Paclitaxel Ado-trastuzumab emtansine + Tucatinib	A Study Evaluating Targeted Therapies in Participants Who Have Advanced Solid Tumors With Genomic Alterations or Protein Expression Patterns Predictive of Response (MyTACTIC)	Completed	USA	0
NCT04022876	Phase I	ALRN-6924 + Carboplatin + Pemetrexed Disodium ALRN-6924 + Topotecan Carboplatin + Pemetrexed Disodium	A Study of ALRN-6924 for the Prevention of Chemotherapy-induced Side Effects (Chemoprotection)	Terminated	USA \| POL \| ITA \| ESP \| DEU	2
NCT03468985	Phase II	Cabozantinib + Nivolumab Cabozantinib + Ipilimumab + Nivolumab Nivolumab	Nivolumab, Cabozantinib S-Malate, and Ipilimumab in Treating Patients With Recurrent Stage IV Non-small Cell Lung Cancer	Completed	USA	0
NCT02185690	Phase I	Binimetinib + Carboplatin + Pemetrexed Disodium	A Phase I/Ib Study of MEK162, a MEK Inhibitor, in Combination With Carboplatin and Pemetrexed in Patients With Non-squamous Carcinoma of the Lung	Completed	CAN	0
NCT04231877	Phase I	Cyclophosphamide + Doxorubicin + Etoposide + Filgrastim + Polatuzumab vedotin-piiq + Prednisone + Rituximab	Polatuzumab Vedotin and Combination Chemotherapy for the Treatment of Untreated Aggressive Large B-cell Lymphoma	Recruiting	USA	0
NCT05570825	Phase II	Pembrolizumab + SX-682	SX-682 With Pembrolizumab for the Treatment of Metastatic or Recurrent Stage IIIC or IV Non-Small Cell Lung Cancer	Recruiting	USA	0
NCT03520686	Phase III	Carboplatin + Nogapendekin alfa inbakicept + Pembrolizumab + Pemetrexed Disodium Cisplatin + Nogapendekin alfa inbakicept + Pembrolizumab + Pemetrexed Disodium Pembrolizumab Carboplatin + Paclitaxel + Pembrolizumab Carboplatin + Nab-paclitaxel + Pembrolizumab Nogapendekin alfa inbakicept + Pembrolizumab Carboplatin + Pembrolizumab + Pemetrexed Disodium Cisplatin + Pembrolizumab + Pemetrexed Disodium Carboplatin + Nab-paclitaxel + Nogapendekin alfa inbakicept + Pembrolizumab	QUILT 2.023: A Study of N-803 in Combination With Current Standard of Care vs Standard of Care as First-Line Treatment for Patients With Stage 3 or 4 NSCLC.	Active, not recruiting	USA	0
NCT01712217	Phase Ib/II	Crizotinib Onalespib	A Study of AT13387 in Patients With Non-Small Cell Lung Cancer (NSCLC) Alone and in Combination With Crizotinib	Completed	USA \| FRA \| ESP \| CAN	1
NCT02784158	Phase I	Brigatinib	An Expanded Access Study of Brigatinib for Patients With ALK-positive Advanced Non-Small Cell Lung Cancer	No longer available	USA	0
NCT03631199	Phase III	Cisplatin Paclitaxel Nab-paclitaxel Carboplatin Canakinumab + Pembrolizumab Pembrolizumab Pemetrexed Disodium	Study of Efficacy and Safety of Pembrolizumab Plus Platinum-based Doublet Chemotherapy With or Without Canakinumab in Previously Untreated Locally Advanced or Metastatic Non-squamous and Squamous NSCLC Subjects (CANOPY-1)	Active, not recruiting	USA \| TUR \| SWE \| SVK \| ROU \| POL \| NOR \| NLD \| LBN \| ITA \| ISL \| HUN \| GRC \| GBR \| FRA \| FIN \| ESP \| DNK \| DEU \| CZE \| CHE \| CAN \| BRA \| AUT \| AUS \| ARG	15
NCT05742607	Phase II	Cisplatin + Durvalumab + IPH5201 + Pemetrexed Disodium Carboplatin + Durvalumab + IPH5201 + Pemetrexed Disodium Carboplatin + Durvalumab + IPH5201 + Paclitaxel	IPH5201 and Durvalumab in Patients With Resectable Non-Small Cell Lung Cancer (MATISSE)	Recruiting	USA \| POL \| HUN \| GRC \| FRA	0
NCT06096844	Phase III	Nab-paclitaxel Pembrolizumab Carboplatin Pemetrexed Disodium	Chemotherapy Combined With Immunotherapy vs Immunotherapy Alone for Older Adults With Stage IIIB-IV Lung Cancer, The ACHIEVE Trial	Recruiting	USA	0
NCT03965468	Phase II	Carboplatin + Durvalumab + Paclitaxel	Immunotherapy, Chemotherapy, Radiotherapy and Surgery for Synchronous Oligo-metastatic NSCLC (CHESS)	Recruiting	NLD \| ITA \| ESP \| CHE	0
NCT03709147	Phase II	Carboplatin + Metformin + Pembrolizumab + Pemetrexed Disodium Cisplatin + Metformin + Pembrolizumab + Pemetrexed Disodium	Metformin Plus/Minus Fasting Mimicking Diet to Target the Metabolic Vulnerabilities of LKB1-inactive Lung Adenocarcinoma (FAME)	Unknown status	ITA	0
NCT05935774	Phase II	Atezolizumab + Trabedersen	OT-101 in Combination With Atezolizumab for the Treatment of Metastatic or Recurrent Non-Small Cell Lung Cancer	Withdrawn	USA	0
NCT02965885	Phase I	Pimitespib	A Study of TAS-116 in Patients With Solid Tumors	Completed	USA \| ITA \| GBR	0
NCT04318938	Phase II	Brigatinib	Advancing Brigatinib Properties in ALK+ NSCLC Patients by Deep Phenotyping	Active, not recruiting	DEU	0
NCT06236438	Phase II	ABBV-151 + Budigalimab + Cisplatin + Pemetrexed Disodium Budigalimab + Carboplatin + Pemetrexed Disodium Cisplatin + Pembrolizumab + Pemetrexed Disodium ABBV-151 + Budigalimab + Carboplatin + Pemetrexed Disodium ABBV-151 + Budigalimab + Pemetrexed Disodium Budigalimab + Cisplatin + Pemetrexed Disodium Carboplatin + Pembrolizumab + Pemetrexed Disodium	Study to Evaluate Adverse Events, Optimal Dose, and Change in Disease Activity, With Livmoniplimab in Combination With Budigalimab Plus Chemotherapy Versus IV Infused Pembrolizumab Plus Chemotherapy in Adult Participants With Untreated Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC) (LIVIGNO-4)	Recruiting	USA \| TUR \| ISR \| AUS	3
NCT05212922	Phase II	Toripalimab-tpzi + YH001	A Study to Evaluate YH001 in Combination With Toripalimab in Subjects With Advanced NSCLC and HCC (YH001)	Withdrawn	AUT \| AUS	3
NCT01970865	Phase II	Lorlatinib Crizotinib	A Study Of PF-06463922 An ALK/ROS1 Inhibitor In Patients With Advanced Non Small Cell Lung Cancer With Specific Molecular Alterations	Completed	USA \| ITA \| FRA \| ESP \| DEU \| CHE \| CAN \| BEL \| AUS	5
NCT04265534	Phase II	Carboplatin + Dexamethasone + Pembrolizumab + Pemetrexed Disodium + Telaglenastat Carboplatin + Dexamethasone + Pembrolizumab + Pemetrexed Disodium	KEAPSAKE: A Study of Telaglenastat (CB-839) With Standard-of-Care Chemoimmunotherapy in 1L KEAP1/NRF2-Mutated, Nonsquamous NSCLC (KEAPSAKE)	Terminated	USA	0
NCT03999710	Phase II	Durvalumab	Determining Whether Durvalumab in Combination With Radiation Therapy Can Prevent the Progression of Non-Small Cell Lung Cancer	Active, not recruiting	USA	0
NCT05757492	Phase Ib/II	CHS-006 + Toripalimab-tpzi	Study to Evaluate Safety and PK of CHS-006 in Combination With Toripalimab in Patients With Advanced Solid Tumors	Terminated	USA	0
NCT05000710	Phase II	Durvalumab Durvalumab + Tremelimumab Tremelimumab	Concomitant Radiotherapy, Tremelimumab & Durvalumab for Advanced NSCLC Patients Progressing on First-line Immunotherapy (CORAL-Lung)	Recruiting	ISR	0
NCT04127110	Phase II	Lorlatinib	Activity of Lorlatinib Based on ALK Resistance Mutations Detected on Blood in ALK Positive NSCLC Patients (ALKALINE)	Active, not recruiting	NOR \| NLD \| GBR \| FRA \| ESP \| BEL	1
NCT06007924	Phase II	Defactinib + RO5126766	A Study of Avutometinib and Defactinib in People With Thyroid Cancer	Recruiting	USA	0
NCT03268057	Phase Ib/II	Avelumab + Pepinemab	VX15/2503 in Combination With Avelumab in Advanced Non-small Cell Lung Cancer	Completed	USA	0
NCT04827576	Phase II	Docetaxel + Hu5F9-G4	Study of Magrolimab in Patients With Solid Tumors (ELEVATELung&UC)	Terminated	USA \| POL \| GBR \| FRA \| ESP	0
NCT02453282	Phase III	Durvalumab Cisplatin + Gemcitabine Carboplatin + Gemcitabine Carboplatin + Paclitaxel Tremelimumab Durvalumab + Tremelimumab Cisplatin + Pemetrexed Disodium Carboplatin + Pemetrexed Disodium	Phase III Open Label First Line Therapy Study of MEDI 4736 (Durvalumab) With or Without Tremelimumab Versus SOC in Non Small-Cell Lung Cancer (NSCLC) (MYSTIC)	Active, not recruiting	USA \| NLD \| ITA \| HUN \| FRA \| ESP \| DEU \| CHE \| CAN \| BEL \| AUS	6
NCT04310007	Phase II	Nab-paclitaxel Gemcitabine Cabozantinib + Nivolumab Cabozantinib Docetaxel Paclitaxel Docetaxel + Ramucirumab	Testing the Addition of the Pill Chemotherapy, Cabozantinib, to the Standard Immune Therapy Nivolumab Compared to Standard Chemotherapy for Non-small Cell Lung Cancer	Active, not recruiting	USA	0
NCT04561362	Phase Ib/II	BT8009 BT8009 + Pembrolizumab	Study BT8009-100 in Subjects With Nectin-4 Expressing Advanced Malignancies	Recruiting	USA \| ITA \| GBR \| FRA \| ESP \| CAN	0
NCT03178552	Phase II	Entrectinib Carboplatin + Cisplatin + Gemcitabine Atezolizumab Carboplatin + Cisplatin + Pemetrexed Disodium Divarasib Atezolizumab + Cobimetinib + Vemurafenib Alectinib	A Study to Evaluate the Efficacy and Safety of Multiple Targeted Therapies as Treatments for Participants With Non-Small Cell Lung Cancer (NSCLC) (B-FAST)	Active, not recruiting	USA \| TUR \| POL \| NZL \| ITA \| ISR \| FRA \| ESP \| DEU \| CAN \| BRA \| BEL \| AUS \| ARG	14
NCT05769075	Phase I	TY-2136b	A Study of TY-2136b in Patients With Advanced Solid Tumors Harboring ALK, ROS1 or NTRK1-3 Alterations	Recruiting	USA	0
NCT04292119	Phase Ib/II	Binimetinib + Lorlatinib Crizotinib + Lorlatinib	Lorlatinib Combinations in Lung Cancer	Unknown status	USA	0
NCT03840915	Phase Ib/II	Bintrafusp alfa + Cisplatin + Pemetrexed Disodium Bintrafusp alfa + Docetaxel Bintrafusp alfa + Carboplatin + Pemetrexed Disodium Bintrafusp alfa + Cisplatin + Gemcitabine Bintrafusp alfa + Carboplatin + Gemcitabine Bintrafusp alfa + Carboplatin + Nab-paclitaxel	M7824 in Combination With Chemotherapy in Stage IV Non-small Cell Lung Cancer (NSCLC)	Completed	USA \| FRA \| BEL	0
NCT05788926	Phase I	TG6050	A Clinical Trial of TG6050 in Patients With Metastatic Non-Small Cell Lung Cancer (Delivir)	Recruiting	FRA	0
NCT04623775	Phase II	Cisplatin + Nab-paclitaxel + Nivolumab + Pemetrexed Disodium Cisplatin + Nivolumab + Paclitaxel + Pemetrexed Disodium Carboplatin + Nab-paclitaxel + Nivolumab + Pemetrexed Disodium Carboplatin + Nivolumab + Paclitaxel + Pemetrexed Disodium Cisplatin + Nab-paclitaxel + Nivolumab + Pemetrexed Disodium + Relatlimab Cisplatin + Nivolumab + Paclitaxel + Pemetrexed Disodium + Relatlimab Carboplatin + Nab-paclitaxel + Nivolumab + Pemetrexed Disodium + Relatlimab Carboplatin + Nivolumab + Paclitaxel + Pemetrexed Disodium + Relatlimab	A Study of Relatlimab Plus Nivolumab in Combination With Chemotherapy vs. Nivolumab in Combination With Chemotherapy as First Line Treatment for Participants With Stage IV or Recurrent Non-small Cell Lung Cancer (NSCLC)	Active, not recruiting	USA \| ROU \| POL \| NLD \| ITA \| IRL \| GBR \| FRA \| ESP \| DEU \| CHE \| BRA \| BEL \| AUT \| AUS \| ARG	3
NCT05241873	Phase Ib/II	BLU-451	(Concerto) Study of BLU-451 in Advanced Cancers With EGFR Exon 20 Insertion Mutations	Active, not recruiting	USA \| CAN	3
NCT02576574	Phase III	Gemcitabine Paclitaxel Cisplatin Avelumab Pemetrexed Disodium Carboplatin	Avelumab in First-line NSCLC (JAVELIN Lung 100)	Completed	USA \| TUR \| SVK \| ROU \| POL \| NZL \| NLD \| LTU \| LBN \| ITA \| ISR \| IRL \| HUN \| HRV \| GRC \| GBR \| FRA \| EST \| ESP \| DNK \| DEU \| CZE \| CYP \| CAN \| BRA \| BGR \| BEL \| AUS	14
NCT02544633	Phase II	Glesatinib	Phase 2 Study of MGCD265 in Patients With Non-Small Cell Lung Cancer With Activating Genetic Alterations in MET	Completed	USA \| POL \| ITA \| HUN \| GBR \| CAN \| AUS	2
NCT03430063	Phase II	Cemiplimab + Ipilimumab Cemiplimab	A Study of REGN2810 and Ipilimumab in Patients With Lung Cancer	Terminated	USA \| POL \| GBR \| FRA \| ESP \| DEU \| BEL	2
NCT03064854	Phase I	Canakinumab + Cisplatin + Pemetrexed Disodium + Spartalizumab Canakinumab + Carboplatin + Spartalizumab Carboplatin + Paclitaxel + Spartalizumab Cisplatin + Pemetrexed Disodium + Spartalizumab Cisplatin + Gemcitabine + Spartalizumab	PDR001 in Combination With Platinum-doublet Chemotherapy and Other Immunology Agents in PD-L1 Unselected, Metastatic NSCLC Patients	Terminated	USA \| NLD \| ITA \| FRA \| ESP \| DEU \| CZE \| CAN \| BEL	3
NCT05715229	Phase II	Carboplatin + Paclitaxel Carboplatin + Pemetrexed Disodium Ipilimumab + Nivolumab	Immune Profile Selection By Fraction of ctDNA in Patients With Advanced NSCLC Treated With Immunotherapy (G360-IIT)	Recruiting	USA	0
NCT04725188	Phase II	Docetaxel Docetaxel + MK-7684A MK-7684A	Pembrolizumab/Vibostolimab Coformulation (MK-7684A) or Pembrolizumab/Vibostolimab Coformulation Plus Docetaxel Versus Docetaxel for Metastatic Non Small Cell Lung Cancer (NSCLC) With Progressive Disease After Platinum Doublet Chemotherapy and Immunotherapy (MK-7684A-002, KEYVIBE-002)	Completed	USA \| POL \| ITA \| ISR \| FRA \| FIN \| ESP \| DNK \| DEU \| CHE \| BRA \| BEL \| AUT \| AUS \| ARG	5
NCT04111705	Phase II	Lorlatinib	Lorlatinib After Failure of First-line Second-generation ALK Kinase Inhibitor in Patients With Advanced ALK-positive Non-small Cell Lung Cancer (ORAKLE)	Active, not recruiting	FRA	0
NCT03896074	Phase II	Atezolizumab + Bevacizumab Atezolizumab	Atezolizumab Versus Atezolizumab Plus Bevacizumab as First Line in NSCLC Patients (BEAT) (BEAT)	Unknown status	ITA	0
NCT04863248	Phase II	Docetaxel + Trilaciclib Docetaxel	Trilaciclib, a CDK 4/6 Inhibitor, in Patients Receiving Docetaxel for Metastatic Non-Small Cell Lung Cancer (NSCLC) (PRESERVE 4)	Terminated	USA	0
NCT04263051	Phase II	Nivolumab + UCPVax	Evaluation of UCPVax Plus Nivolumab as Second Line Therapy in Advanced Non Small Cell Lung Cancer (Optim-UCPVax)	Active, not recruiting	FRA	0
NCT04146571	Expanded access	Ensartinib	Expanded Access to Ensartinib for Participants With ALK+ NSCLC	Available	USA	0
NCT05398094	Phase II	Sotorasib	Clinical Trial of AMG510 in Stage III Unresectable NSCLC KRAS p.G12C Patients and Ineligible for Chemo-radiotherapy (MERIT-lung)	Recruiting	ESP	0
NCT02554812	Phase Ib/II	Avelumab + PF-04518600 Avelumab + PD 0360324 Avelumab + Utomilumab Avelumab + PF-04518600 + Utomilumab	A Study Of Avelumab In Combination With Other Cancer Immunotherapies In Advanced Malignancies (JAVELIN Medley)	Terminated	USA \| POL \| GBR \| FRA \| CAN \| AUS	2
NCT05358548	Phase II	Carboplatin + Paclitaxel + Pembrolizumab Carboplatin + Pembrolizumab + Pemetrexed Disodium Carboplatin + Fluorouracil + Pembrolizumab	ATATcH Alternating Treatment Plans for Advanced Cancer	Recruiting	USA	0
NCT05132075	Phase III	JDQ443 Docetaxel	Study of JDQ443 in Comparison With Docetaxel in Participants With Locally Advanced or Metastatic KRAS G12C Mutant Non-small Cell Lung Cancer (KontRASt-02)	Active, not recruiting	USA \| TUR \| SVN \| ROU \| LBN \| ITA \| ISL \| HUN \| GRC \| FIN \| ESP \| CAN \| AUS \| ARG	12
NCT04385368	Phase III	Durvalumab	Phase III Study to Determine the Efficacy of Durvalumab in Combination With Chemotherapy in Completely Resected Stage II-III Non-small Cell Lung Cancer (NSCLC) (MERMAID-1)	Completed	USA \| TUR \| SWE \| ROU \| POL \| NLD \| ITA \| ISR \| HUN \| GRC \| FRA \| ESP \| DNK \| DEU \| CZE \| CHE \| CAN \| BRA \| BGR \| BEL \| AUS \| ARG	11
NCT04716946	Phase II	Durvalumab	Treating Early-stage Non-Small Cell Lung Cancer With Durvalumab and Radiation Therapy	Recruiting	USA	0
NCT04849273	Phase Ib/II	TPX-0131	A Study of TPX-0131, a Novel Oral ALK Tyrosine Kinase Inhibitor, in Patients With ALK+ Advanced or Metastatic NSCLC	Terminated	USA \| AUS	1
NCT02400814	Phase I	Atezolizumab	MPDL3280A and Stereotactic Ablative Radiotherapy in Patients With Non-small Cell Lung Cancer	Terminated	USA	0
NCT03425331	Phase II	Ipilimumab + Nivolumab	Biomarkers of Response to Ipilimumab and Nivolumab in First-line NSCLC	Terminated	USA	0
NCT03516981	Phase II	MK-1308 + Pembrolizumab MK-4280 + Pembrolizumab Lenvatinib + Pembrolizumab	A Study of Biomarker-Directed, Pembrolizumab (MK-3475) Based Combination Therapy for Advanced Non-Small Cell Lung Cancer (MK-3475-495/KEYNOTE-495)	Active, not recruiting	USA \| POL \| ITA \| IRL \| GBR \| ESP \| CHE \| CAN \| AUS	7
NCT05061550	Phase II	Durvalumab + Monalizumab Durvalumab + Oleclumab	Neoadjuvant and Adjuvant Treatment in Resectable Non-small Cell Lung Cancer (NeoCOAST-2)	Recruiting	USA \| TUR \| ITA \| IRL \| HUN \| FRA \| ESP \| CAN \| BEL	3
NCT04227028	Phase I	Bevacizumab + Brigatinib	Brigatinib and Bevacizumab for the Treatment of ALK-Rearranged Locally Advanced, Metastatic, or Recurrent NSCLC	Active, not recruiting	USA	0
NCT03270176	Phase I	Avelumab + Xevinapant	A Dose-Finding Study of the Second Mitochondrial Activator of Caspases (SMAC) Mimetic Debio 1143 When Given in Combination With Avelumab to Participants With Advanced Solid Malignancies and to Participants With Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) After Platinum-Based Therapy	Completed	ROU \| POL \| CAN	0
NCT02350764	Phase II	Ipilimumab + Nivolumab	Evaluate the Mediators of Sensitivity and Resistance to Nivolumab Plus Ipilimumab in Patients With Advanced NSCLCs	Completed	USA	0
NCT04311710	Phase Ib/II	Ipilimumab + Nivolumab Ipilimumab + Nivolumab + rHuPH20	A Study Evaluating the Drug Levels of Iplimumab Given Under the Skin Alone and in Combination With Nivolumab in Multiple Tumor Types (CheckMate 76U)	Terminated	USA \| NZL \| ITA	0
NCT05117242	Phase II	GEN1046 + Pembrolizumab GEN1046	Safety and Efficacy Study of GEN1046 as a Single Agent or in Combination With Pembrolizumab for Treatment of Recurrent (Non-small Cell) Lung Cancer	Active, not recruiting	USA \| POL \| NLD \| ITA \| GBR \| FRA \| ESP \| DEU	1
NCT02473497	Expanded access	Crizotinib	Crizotinib (Xalkori) Expanded Access Protocol For The Treatment Of Adult Or Pediatric Patients	No longer available	USA	0
NCT05215340	Phase III	Pembrolizumab Datopotamab deruxtecan + Pembrolizumab	Study of Dato-DXd Plus Pembrolizumab vs Pembrolizumab Alone in the First-line Treatment of Subjects With Advanced or Metastatic NSCLC Without Actionable Genomic Alterations (TROPION-Lung08)	Recruiting	USA \| TUR \| ROU \| POL \| NLD \| ITA \| HUN \| GRC \| GBR \| FRA \| ESP \| DEU \| CHE \| CAN \| BRA \| BEL \| AUT \| AUS \| ARG	9
NCT06000358		Pembrolizumab	The Effect of Combined Cryotherapy and Immunotherapy on Systemic T Cell Changes and Clinical Outcomes in Metastatic Non-small Cell Lung Cancer (LUCACRIMUNO)	Recruiting	LTU	0
NCT02504489	Phase III	Docetaxel Docetaxel + Plinabulin	Docetaxel + Plinabulin Compared to Docetaxel + Placebo in Patients With Advanced NSCLC (DUBLIN-3)	Completed	USA \| AUS	1
NCT05624996	Phase III	Cisplatin + Durvalumab + Etoposide Carboplatin + Durvalumab + Pemetrexed Disodium Cisplatin + Durvalumab + Pemetrexed Disodium Carboplatin + Durvalumab + Paclitaxel	Testing the Addition of High Dose, Targeted Radiation to the Usual Treatment for Locally-Advanced Inoperable Non-small Cell Lung Cancer	Recruiting	USA	0
NCT04108026	Phase II	Durvalumab	Immunotherapy in Patient With Poor General Condition (SAVIMMUNE)	Active, not recruiting	FRA	0
NCT04837716	Phase I	Bevacizumab + Carboplatin + Ensartinib + Pemetrexed Disodium	Ensartinib, Carboplatin, Pemetrexed and Bevacizumab for the Treatment of Stage IIIC or IV or Recurrent ALK-Positive Non-small Cell Lung Cancer	Active, not recruiting	USA	0
NCT02264990	Phase III	Pemetrexed Disodium Carboplatin Paclitaxel Veliparib Cisplatin	Study Comparing Veliparib Plus Carboplatin and Paclitaxel Versus Investigator's Choice of Standard Chemotherapy in Subjects Receiving First Cytotoxic Chemotherapy for Metastatic or Advanced Non-Squamous Non-Small Cell Lung Cancer Who Are Current or Former Smokers	Completed	USA \| TUR \| NZL \| NLD \| ISR \| HUN \| GBR \| FIN \| ESP \| DNK \| DEU \| CZE \| CAN \| AUS \| ARG	5
NCT05048797	Phase III	Cisplatin + Pembrolizumab + Pemetrexed Disodium Carboplatin + Pembrolizumab + Pemetrexed Disodium Trastuzumab deruxtecan	A Study to Investigate the Efficacy and Safety of Trastuzumab Deruxtecan as the First Treatment Option for Unresectable, Locally Advanced/Metastatic Non-Small Cell Lung Cancer With HER2 Mutations	Recruiting	USA \| TUR \| POL \| NLD \| ITA \| FRA \| ESP \| DNK \| DEU \| CAN \| BRA \| BEL \| AUT	7
NCT05557591	Phase II	Cemiplimab BNT116 + Cemiplimab	A Trial to Learn How the Cancer Vaccine BNT116 in Combination With Cemiplimab Works and How Safe the Combination is in Adults With Advanced Non-small Cell Lung Cancer (EMPOWERVAX Lung 1)	Recruiting	USA \| TUR \| ESP \| DEU	3
NCT05525338	FDA approved	Alectinib	Comparison of Standard Dose Alectinib to Alectinib in Adjusted Dose Based on Alectinib Bloodlevels (ADAPT ALEC)	Recruiting	NLD \| FRA	0
NCT05313009	Phase Ib/II	Sotorasib + TH-4000	Tarlox and Sotorasib in Patients With KRAS G12C Mutations	Terminated	USA	0
NCT02542293	Phase III	Cisplatin + Gemcitabine Carboplatin + Gemcitabine Durvalumab + Tremelimumab Carboplatin + Paclitaxel Cisplatin + Pemetrexed Disodium Carboplatin + Pemetrexed Disodium	Study of Durvalumab With Tremelimumab Versus SoC as 1st Line Therapy in Metastatic Non Small-Cell Lung Cancer (NSCLC) (NEPTUNE) (NEPTUNE)	Active, not recruiting	USA \| TUR \| SWE \| ROU \| POL \| ISR \| GRC \| GBR \| FIN \| DNK \| BRA \| BGR \| ARG	16
NCT02898116	Phase Ib/II	Durvalumab + Ensartinib Ensartinib	A Study of ALK Inhibitor, Ensartinib, and Anti-PD-L1, Durvalumab, in Subjects With ALK-rearranged Non-small Cell Lung Cancer	Completed	USA	0
NCT05703555	Phase II	SAR408701	INTRUSION: Unraveling the INTRatUmoral PK/PD relatION for SAR408701 (INTRUSION)	Withdrawn	NLD	0
NCT05255302	Phase II	Pembrolizumab + Pemetrexed Disodium Cisplatin + Paclitaxel + Pembrolizumab Carboplatin + Paclitaxel + Pembrolizumab	De-escalation Immunotherapy mAintenance Duration Trial for Stage IV Lung Cancer Patients With Disease Control After Chemo-immunotherapy Induction (DIAL)	Recruiting	FRA	0
NCT02271139	Phase III	Alectinib	Expanded Access Study of Alectinib for Patients With ALK-Rearranged Non-Small Cell Lung Cancer Previously Treated With Crizotinib	No longer available	USA	0
NCT04551521	Phase II	Atezolizumab Atezolizumab + Ipatasertib Atezolizumab + Pertuzumab + Trastuzumab Atezolizumab + Cobimetinib Alectinib Atezolizumab + Cobimetinib + Vemurafenib	CRAFT: The NCT-PMO-1602 Phase II Trial	Recruiting	DEU	0
NCT03472560	Phase II	Avelumab + Axitinib	A Study of Avelumab in Combination With Axitinib In Non-Small Cell Lung Cancer (NSCLC) or Urothelial Cancer (Javelin Medley VEGF)	Terminated	USA \| POL \| ITA \| HUN \| ESP	3
NCT03840902	Phase II	Carboplatin + Paclitaxel Bintrafusp alfa Cisplatin + Etoposide Durvalumab Bintrafusp alfa + Cisplatin + Etoposide Bintrafusp alfa + Carboplatin + Paclitaxel Bintrafusp alfa + Cisplatin + Pemetrexed Disodium Cisplatin + Pemetrexed Disodium	M7824 With cCRT in Unresectable Stage III Non-small Cell Lung Cancer (NSCLC)	Terminated	USA \| NLD \| FRA \| ESP \| DEU \| CZE \| CAN \| BRA \| BEL \| AUS \| ARG	4
NCT03215706	Phase III	Carboplatin + Cisplatin + Paclitaxel + Pemetrexed Disodium Ipilimumab + Nivolumab	A Study of Nivolumab and Ipilimumab Combined With Chemotherapy Compared to Chemotherapy Alone in First Line NSCLC (CheckMate 9LA)	Active, not recruiting	USA \| ROU \| POL \| ITA \| IRL \| GBR \| FRA \| ESP \| DEU \| CAN \| BRA \| BEL \| AUS \| ARG	5
NCT03991819	Phase I	Binimetinib + Pembrolizumab	Study of Binimetinib in Combination With Pembrolizumab in Advanced Non-Small Cell Lung Cancer	Recruiting	CAN	0
NCT02289144	Phase II	Ceritinib	Ceritinib in Mutation and Oncogene Directed Therapy in Thyroid Cancer	Withdrawn	USA	0
NCT04884282	Phase II	Docetaxel + OSE 2101 Docetaxel Nivolumab + OSE 2101	Efficacy of Tedopi Plus Docetaxel or Tedopi Plus Nivolumab as Second-line Therapy in Metastatic Non-small-cell Lung Cancer Progressing After First-line Chemo-immunotherapy (Combi-TED) (COMBI-TED)	Recruiting	ITA \| FRA \| ESP	0
NCT02696993	Phase Ib/II	Nivolumab Ipilimumab + Nivolumab	Nivolumab and Radiation Therapy With or Without Ipilimumab in Treating Patients With Brain Metastases From Non-small Cell Lung Cancer	Active, not recruiting	USA	0
NCT01871805	Phase Ib/II	Alectinib	A Study of CH5424802/RO5424802 in Patients With ALK-Rearranged Non-Small Cell Lung Cancer	Completed	USA \| CAN	0
NCT04250246	Phase II	Ipilimumab + Nivolumab Guadecitabine + Ipilimumab + Nivolumab	A Study of NIVO Plus IPI and Guadecitabine or NIVO Plus IPI in Melanoma and NSCLC Resistant to Anti-PD1/PDL1 (NIBIT-ML1)	Not yet recruiting	ITA	0
NCT03156114	Phase I	Ezabenlimab Miptenalimab	This Study Tests the New Medicine BI 754111 Alone or in Combination With Another New Substance BI 754091 in Patients With Advanced Cancer. The Study Tests Different Doses to Find the Best Dose for Continuous Treatment.	Completed	USA \| POL \| GBR \| ESP \| CAN	0
NCT04738487	Phase III	Pembrolizumab MK-7684A	Coformulation of Pembrolizumab/Vibostolimab (MK-7684A) Versus Pembrolizumab (MK-3475) Monotherapy for Programmed Cell Death 1 Ligand 1 (PD-L1) Positive Metastatic Non-Small Cell Lung Cancer (MK-7684A-003, KEYVIBE-003)	Active, not recruiting	USA \| TUR \| ROU \| HUN \| CAN \| BRA	17
NCT03953235	Phase Ib/II	GRT-C903 + GRT-R904 + Ipilimumab + Nivolumab	A Study of a Personalized Cancer Vaccine Targeting Shared Neoantigens	Completed	USA	0
NCT05565378	Phase II	Dostarlimab-gxly Dostarlimab-gxly + EOS-448 Pembrolizumab	A Platform Study of Novel Immunotherapy Combinations in Participants With Previously Untreated, Advanced/Metastatic Non-Small-Cell Lung Cancer	Recruiting	USA \| TUR \| POL \| NLD \| ITA \| HUN \| GRC \| GBR \| FRA \| FIN \| ESP \| DEU \| BRA \| BEL \| ARG	7
NCT03591731	Phase II	Nivolumab Ipilimumab + Nivolumab	Nivolumab +/- Ipilimumab in Patients With Advanced, Refractory Pulmonary or Gastroenteropancreatic Poorly Differentiated Neuroendocrine Tumors (NECs) (NIPINEC)	Active, not recruiting	FRA	0
NCT04892472	Phase II	Pembrolizumab	EF-36/Keynote B36: A Pilot, Randomized, Open-label Study of Tumor Treating Fields (TTFields, 150 kHz) Concomitant With Pembrolizumab for First Line Treatment of Advanced or Metastatic Non-small Cell Lung Cancer (KEYNOTE B36)	Recruiting	USA	0
NCT04921358	Phase III	Docetaxel Sitravatinib + Tislelizumab	Tislelizumab in Combination With Sitravatinib in Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer	Terminated	AUS	1
NCT05650879	Phase I	ELVN-002 ELVN-002 + Trastuzumab deruxtecan Ado-trastuzumab emtansine + ELVN-002	ELVN-002 in HER2 Mutant Non-Small Cell Lung Cancer (HER2)	Recruiting	USA \| ITA \| FRA \| ESP \| AUS	2
NCT04995523	Phase Ib/II	AZD2936	A Study of AZD2936 Anti-TIGIT/Anti-PD-1 Bispecific Antibody in Participants With Advanced or Metastatic NSCLC (ARTEMIDE-01)	Active, not recruiting	USA \| NLD \| FRA \| ESP \| DNK \| BRA \| BEL \| AUS	6
NCT01744652	Phase I	Crizotinib + Dasatinib	Dasatinib and Crizotinib in Advanced Cancer	Completed	USA	0
NCT05598853	Phase I	Ipilimumab + Nivolumab	Intrathecal Double Checkpoint Inhibition (IT-IO)	Recruiting	CHE	0
NCT03083691	Phase II	Ipilimumab + Nivolumab	BIOLUMA: Biomarkers for Nivolumab and Ipilimumab and Evaluation of the Combination in Lung Cancer	Completed	DEU	0
NCT06680050	Phase II	Ceralasertib + Durvalumab	Phase II Study of Radiotherapy Followed by Durvalumab (MEDI4736) and Ceralasertib (AZD6738) in Stage III NSCLC Patients With Thoracic Relapses +/- Oligometastases After PACIFIC Regimen (AUSTRAL) (AUSTRAL)	Not yet recruiting	ITA \| CHE	0
NCT03469960	Phase III	Ipilimumab + Nivolumab	Double Immune Checkpoint Inhibitors in PD-L1-positive Stage IV Non-small Lung CancEr (DICIPLE)	Active, not recruiting	FRA	0
NCT05006794	Phase I	GS-9716 + Sacituzumab govitecan-hziy GS-9716 Docetaxel + GS-9716	Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of GS-9716 as Monotherapy and in Combination With Anticancer Therapies in Adults With Solid Malignancies	Recruiting	USA \| ISR	0
NCT06312137	Phase III	Carboplatin + Paclitaxel + Pembrolizumab Cisplatin + Pembrolizumab + Pemetrexed Disodium Cisplatin + Gemcitabine + Pembrolizumab Pembrolizumab + SKB264	A Study to Assess Efficacy and Safety of Pembrolizumab With or Without Sacituzumab Tirumotecan (MK- 2870) in Adult Participants With Resectable Non Small Cell Lung Cancer (NSCLC) Not Achieving Pathological Complete Response (pCR) (MK-2870-019)	Recruiting	USA \| ROU \| POL \| NOR \| NLD \| ISR \| GRC \| FRA \| ESP \| DEU \| CHE \| CAN \| BRA \| BEL \| AUT \| AUS \| ARG	8
NCT02259582	Phase II	Carboplatin + Pemetrexed Disodium Demcizumab	A Study of Carboplatin, Pemetrexed Plus Placebo vs Carboplatin, Pemetrexed Plus 1 or 2 Truncated Courses of Demcizumab in Subjects With Non-Squamous Non-Small Cell Lung Cancer	Completed	USA \| ITA \| ESP \| BEL \| AUS	0
NCT05438329	Phase Ib/II	DB-1305	First-in-human Study of DB-1305/BNT325 for Advanced/Metastatic Solid Tumors	Recruiting	USA	2
NCT05815186	Phase II	Ladarixin + Sotorasib	Ladarixin With Sotorasib in Advanced NSCLC - Phase II	Withdrawn	USA	0
NCT03977194	Phase III	Atezolizumab + Carboplatin + Paclitaxel Carboplatin + Paclitaxel	Atezolizumab in Elderly Patients With Advanced Non-Small-Cell Lung Cancer and Receiving Carboplatin Paclitaxel Chemotherapy (ELDERLY)	Active, not recruiting	FRA	0
NCT06362369	Phase Ib/II	7HP349 + Ipilimumab + Nivolumab	A Study of Oral 7HP349 (Alintegimod) in Combination With Ipilimumab Followed by Nivolumab Monotherapy	Recruiting	USA	0
NCT04367311	Phase II	Atezolizumab + Cisplatin + Pemetrexed Disodium Atezolizumab + Cisplatin + Docetaxel	Adjuvant Treatment With Cisplatin-based Chemotherapy Plus Concomitant Atezolizumab in Patients With Stage I (Tumors >= 4cm), IIA, IIB, and Select Stage III [Any T1-3 N1-2 and T4N0-2] Resected Non-small Cell Lung Cancer (NSCLC) and the Clearance of Circulating Tumor DNA (ctDNA)	Recruiting	USA	0
NCT02737501	Phase III	Brigatinib Crizotinib	ALTA-1L Study: A Phase 3 Study of Brigatinib Versus Crizotinib in Anaplastic Lymphoma Kinase (ALK)-Positive Advanced Non-small Cell Lung Cancer (NSCLC) Participants (ALTA-1L)	Completed	USA \| SWE \| NOR \| NLD \| LUX \| ITA \| GBR \| FRA \| ESP \| DNK \| DEU \| CHE \| CAN \| AUT \| AUS	4
NCT02422589	Phase I	Warfarin Midazolam Ceritinib	A Phase I, Multi-center, Open Label, Drug-drug Interaction Study to Assess the Effect of Ceritinib on the Pharmacokinetics of Warfarin and Midazolam in Patients With ALK-positive Advanced Tumors	Completed	USA \| ITA \| ESP \| DNK	0
NCT03774732	Phase III	Carboplatin + Pembrolizumab + Pemetrexed Disodium Carboplatin + Paclitaxel + Pembrolizumab Cisplatin + Pembrolizumab + Pemetrexed Disodium	PD-1 Inhibitor and Chemotherapy With Concurrent Irradiation at Varied Tumour Sites in Advanced Non-small Cell Lung Cancer (NIRVANA-LUNG)	Active, not recruiting	FRA	1
NCT03267316	Phase Ib/II	Nidanilimab Cisplatin + Gemcitabine + Nidanilimab Gemcitabine + Nab-paclitaxel + Nidanilimab	A First-in-Human Study of CAN04 in Patients With Solid Malignant Tumors (CANFOUR)	Completed	SWE \| NOR \| NLD \| LVA \| LTU \| EST \| ESP \| DNK \| DEU \| BEL \| AUT	0
NCT05200481	Phase II	Brigatinib + Carboplatin + Pemetrexed Disodium Brigatinib	Study of Safety and Efficacy of Brigatinib Plus Chemotherapy or Brigatinib Only in Advanced ALK-Positive Lung Cancer (MASTERPROTOCOL ALK)	Active, not recruiting	FRA	0
NCT02568267	Phase II	Entrectinib	Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (Fusions) (STARTRK-2)	Active, not recruiting	USA \| POL \| NLD \| ITA \| GBR \| FRA \| ESP \| DEU \| BEL \| AUS	6
NCT05815173	Phase I	Ladarixin + Sotorasib	Ladarixin With Sotorasib in Advanced NSCLC	Recruiting	USA	0
NCT04683250	Phase Ib/II	Vepafestinib	Study of RET Inhibitor TAS0953/HM06 in Patients With Advanced Solid Tumors With RET Gene Abnormalities ((MARGARET))	Recruiting	USA	1
NCT03425006	Phase II	Itacitinib + Pembrolizumab	Pembrolizumab and Itacitinib (INCB039110) for NSCLC	Terminated	USA	0
NCT05450562	Phase Ib/II	Atezolizumab + SAR444200 SAR444200	Dose Escalation and Expansion Study of SAR444200-based Regimen in Adult Participants With Advanced Solid Tumors	Recruiting	USA \| CAN	3
NCT03088930	Phase II	Crizotinib	Evaluating Crizotinib in the Neoadjuvant Setting in Patients With Non-small Cell Lung Cancer	Completed	USA	0
NCT06116786	Phase I	Cetrelimab + JNJ-86974680	A Study of JNJ-86974680 in Participants With Advanced Non-small Cell Lung Cancer	Recruiting	USA \| ESP \| DEU	1
NCT05709821	Phase Ib/II	Pembrolizumab IMM60 IMM60 + Pembrolizumab	IMM60 and Pembrolizumab in Melanoma and NSCLC	Terminated	USA \| GBR \| ESP	0
NCT05240131	Phase Ib/II	Atezolizumab + GB1211	A Study to Investigate the Safety and Efficacy of GB1211 (a Galectin-3 Inhibitor) in Combination With Atezolizumab in Patients With Non-Small Cell Lung Cancer (NSCLC).	Active, not recruiting	POL \| FRA \| ESP	0
NCT03317496	Phase II	Avelumab + Cisplatin + Gemcitabine Avelumab + Carboplatin + Pemetrexed Disodium	Safety And Efficacy Study Of Avelumab Plus Chemotherapy With Or Without Other Anti-Cancer Immunotherapy Agents In Patients With Advanced Malignancies	Terminated	USA \| ITA \| HUN \| GBR \| ESP \| CZE \| CAN \| AUS	0
NCT03130764	Phase II	Durvalumab + Tremelimumab	Durvalumab and Tremelimumab for Adjuvant Therapy of Resected NSCLC	Withdrawn		0
NCT01948141	Phase II	Nintedanib	Nintedanib in Treating Patients With Advanced Non-Small Cell Lung Cancer Who Have Failed Up to Two Previous Chemotherapy Regimens	Completed	USA	0
NCT03158883	Phase I	Avelumab	UCDCC#270: Avelumab and Stereotactic Ablative Radiotherapy in Non-responding and Progressing NSCLC Patients	Completed	USA	0
NCT05555732	Phase III	Datopotamab deruxtecan + Pembrolizumab Carboplatin + Pembrolizumab + Pemetrexed Disodium Cisplatin + Pembrolizumab + Pemetrexed Disodium Carboplatin + Datopotamab deruxtecan + Pembrolizumab Cisplatin + Datopotamab deruxtecan + Pembrolizumab	Datopotamab Deruxtecan (Dato-DXd) and Pembrolizumab With or Without Platinum Chemotherapy in 1L Non-Small Cell Lung Cancer (TROPION-Lung07)	Recruiting	USA \| TUR \| ROU \| POL \| NLD \| ITA \| HUN \| GRC \| FRA \| ESP \| DEU \| CHE \| CAN \| BRA \| BEL \| AUT \| AUS \| ARG	8
NCT06099782	Phase II	MK-3475A Pembrolizumab	A Study of Participant Reported Preference for Subcutaneous Pembrolizumab Coformulated With Hyaluronidase (MK-3475A) Over Intravenous Pembrolizumab (MK-3475) Formulation in Multiple Tumor Types (MK-3475A-F11)	Recruiting	USA \| TUR \| POL \| NZL \| FRA \| AUS \| ARG	3
NCT05722886	Phase II	Cobimetinib + Vemurafenib Alectinib Pertuzumab + Trastuzumab Entrectinib Atezolizumab	DETERMINE (Determining Extended Therapeutic Indications for Existing Drugs in Rare Molecularly Defined Indications Using a National Evaluation Platform Trial) - Master Screening Protocol (DETERMINE)	Recruiting	GBR	0
NCT02823990	Phase II	MVA-MUC1-IL2 vaccine + Nivolumab	TG4010 and Nivolumab in Patients With Lung Cancer	Completed	USA	0
NCT02572453	Phase II	Onalespib	Testing AT13387 (Onalespib) in Patients With Relapsed/Refractory ALK+ Anaplastic Large Cell Lymphoma (ALCL), Mantle Cell Lymphoma (MCL), and BCL6+ Diffuse Large B Cell Lymphoma (DLBCL)	Terminated	USA	0
NCT02864251	Phase III	Carboplatin + Nivolumab + Pemetrexed Disodium Cisplatin + Pemetrexed Disodium Cisplatin + Nivolumab + Pemetrexed Disodium Ipilimumab + Nivolumab Carboplatin + Pemetrexed Disodium	A Study of Nivolumab + Chemotherapy or Nivolumab + Ipilimumab Versus Chemotherapy in NSCLC Patients With EGFR Mutation Who Failed 1L or 2L EGFR TKI Therapy (CheckMate722)	Completed	USA \| FRA \| ESP \| CAN	6
NCT06378892	Phase II	Cisplatin + Lorlatinib + Pemetrexed Disodium Carboplatin + Lorlatinib + Pemetrexed Disodium Lorlatinib + Pemetrexed Disodium	A Study to Evaluate the Combination of Platinum-pemetrexed Based Chemotherapy Plus Lorlatinib in ALK Positive Non-Small Cell Lung Cancer (NSCLC) With Exclusively Extracranial Disease Progression on Lorlatinib (ALK-PPL)	Recruiting	ITA	0
NCT04151563	Phase Ib/II	Lucitanib + Nivolumab Docetaxel Cabozantinib + Nivolumab Cabozantinib + Ipilimumab + Nivolumab Docetaxel + Nivolumab Docetaxel + Nivolumab + Ramucirumab	A Phase 1/2 Study Evaluating Multiple Nivolumab Combination Therapy in Participants With Stage IV Non-small Cell Lung Cancer That Has Spread or Has Reoccurred After Failure of Chemotherapy and Immunotherapy	Withdrawn	USA \| ROU \| POL \| NOR \| NLD \| GRC \| DNK \| BEL \| ARG	1
NCT02382406	Phase Ib/II	Pembrolizumab Carboplatin + Nab-paclitaxel + Pembrolizumab	Carboplatin/Nab-Paclitaxel and Pembrolizumab in NSCLC	Terminated	USA	0
NCT06561386	Phase III	Carboplatin + Pembrolizumab + Pemetrexed Disodium Cisplatin + Nivolumab + Pemetrexed Disodium + Relatlimab Cisplatin + Pembrolizumab + Pemetrexed Disodium Carboplatin + Nivolumab + Pemetrexed Disodium + Relatlimab	A Study to Compare the Efficacy of Nivolumab and Relatlimab Plus Chemotherapy vs Pembrolizumab Plus Chemotherapy for Stage IV/Recurrent Non-squamous Non-small Cell Lung Cancer With PD-L1 1-49% (RELATIVITY1093)	Recruiting	USA \| ROU \| POL \| NLD \| ITA \| IRL \| GBR \| FRA \| ESP \| DNK \| DEU \| CHE \| BRA \| BEL \| AUT \| AUS \| ARG	7
NCT04450901	Phase I	YBL-006	Dose Escalation/Dose Expansion Study of YBL-006 in Patients With Advanced Solid Tumors	Active, not recruiting	AUS	2
NCT02314364	Phase II		A Trial of Integrating SBRT With Targeted Therapy in Stage IV Oncogene-driven NSCLC	Completed	USA	0
NCT03625323	Phase II	Eftilagimod alpha + Pembrolizumab	Combination Study With Soluble LAG-3 Fusion Protein Eftilagimod Alpha (IMP321) and Pembrolizumab in Patients With Previously Untreated Unresectable or Metastatic NSCLC, or Recurrent PD-X Refractory NSCLC or With Recurrent or Metastatic HNSCC (TACTI-002)	Active, not recruiting	USA \| GBR \| ESP \| AUS	1
NCT04169841	Phase II	Durvalumab + Olaparib + Tremelimumab	Study Evaluating the Efficacy of a Double Immunotherapy Combined With Olaparib in Patients With Solid Cancers and Carriers of Homologous Recombination Repair Genes After Olaparib Treatment (GUIDE2REPAIR)	Active, not recruiting	FRA	0
NCT05984277	Phase III	Carboplatin + MEDI5752 + Pemetrexed Disodium Carboplatin + MEDI5752 + Paclitaxel Carboplatin + Pembrolizumab + Pemetrexed Disodium Carboplatin + Paclitaxel + Pembrolizumab	A Global Study of Volrustomig (MEDI5752) Plus Chemotherapy Versus Pembrolizumab Plus Chemotherapy for Participants With Metastatic Non-small Cell Lung Cancer. (eVOLVE-Lung02)	Recruiting	USA \| TUR \| SVK \| POL \| NLD \| ITA \| HUN \| GBR \| FRA \| ESP \| DEU \| CZE \| CAN \| BRA \| BEL \| AUT \| AUS \| ARG	8
NCT03904108	Phase II	Ramucirumab	Platinum-Based Chemotherapy Plus Ramucirumab in Patients With Advanced NSCLC Who Have Progressed on First Line Anti-PD-1 Immunotherapy	Terminated	USA	0
NCT03003962	Phase III	Durvalumab Cisplatin + Gemcitabine Carboplatin + Gemcitabine Carboplatin + Pemetrexed Disodium Cisplatin + Pemetrexed Disodium Carboplatin + Paclitaxel	Study of Durvalumab Alone or Chemotherapy for Patients With Advanced Non Small-Cell Lung Cancer (PEARL)	Active, not recruiting	USA \| TUR \| POL \| NLD \| HUN \| AUS	6
NCT03048136	Phase III	Ipilimumab + Nivolumab	A Safety Study of Nivolumab in Combination With Ipilimumab in Participants With Advanced Non-small Cell Lung Cancer (CheckMate 955)	Withdrawn	USA \| DEU \| CAN \| ARG	1
NCT03087448	Phase Ib/II	Ceritinib + Trametinib	Ceritinib + Trametinib in Patients With Advanced ALK-Positive Non-Small Cell Lung Cancer (NSCLC)	Terminated	USA	0
NCT02352948	Phase III	Durvalumab Vinorelbine Durvalumab + Tremelimumab Gemcitabine Erlotinib Tremelimumab	A Global Study to Assess the Effects of MEDI4736 (Durvalumab), Given as Monotherapy or in Combination With Tremelimumab Determined by PD-L1 Expression Versus Standard of Care in Patients With Locally Advanced or Metastatic Non Small Cell Lung Cancer (ARCTIC)	Completed	USA \| ROU \| POL \| NLD \| ITA \| ISR \| HUN \| GRC \| GBR \| FRA \| ESP \| DEU \| CZE \| CAN \| BGR \| BEL \| AUS	9
NCT05877430	Phase Ib/II	CJRB-101 + Pembrolizumab	Safety, Tolerability, and Preliminary Efficacy of CJRB-101 With Pembrolizumab in Subjects With Selected Types of Advanced or Metastatic Cancer	Recruiting	USA	1
NCT06173505	Phase Ib/II	Carboplatin + Pemetrexed Disodium + XmAb20717 Carboplatin + Pembrolizumab + Pemetrexed Disodium	Study of Vudalimab or Pembrolizumab in Combination With Chemotherapy as First-line Treatment in Patients With Advanced NSCLC	Recruiting	USA \| NLD \| ESP \| BEL	2
NCT04866017	Phase III	Durvalumab BGBA1217 + Tislelizumab Tislelizumab	A Study to Compare Ociperlimab Plus Tislelizumab Versus Durvalumab Following Concurrent Chemoradiotherapy (cCRT) in Patients With Stage III Unresectable Non-Small Cell Lung Cancer	Terminated	USA \| ESP \| AUS	2
NCT05144997	FDA approved	Lorlatinib	Lorlatinib Continuation Study	Active, not recruiting	USA \| FRA \| ESP	5
NCT03256136	Phase II	Carboplatin + Nivolumab + Pemetrexed Disodium Ipilimumab + Nivolumab	A Phase II Study of Nivolumab in Combination With Carboplatin and Pemetrexed, or Nivolumab in Combination With Ipilimumab, in Patients With Advanced, EGFR-mutant or ALK-rearranged, Non-Small Cell Lung Cancer	Completed	USA	0
NCT03793179	Phase III	Carboplatin + Pembrolizumab + Pemetrexed Disodium Pembrolizumab + Pemetrexed Disodium Pembrolizumab Carboplatin + Pemetrexed Disodium	Testing the Timing of Pembrolizumab Alone or With Chemotherapy as First Line Treatment and Maintenance in Non-small Cell Lung Cancer	Active, not recruiting	USA \| CAN	1
NCT01449461	Phase Ib/II	Brigatinib	A Phase 1/2 Study of the Oral ALK/EGFR Inhibitor AP26113	Completed		0
NCT04274907	Phase I	Pembrolizumab + Venetoclax Pembrolizumab	A Safety Study of Oral Venetoclax in Combination With Intravenous Pembrolizumab in Adult Participants With Previously Untreated Non-Small Cell Lung Cancer (NSCLC) With High Programmed Cell Death Ligand-1 (PD-L1) Expression	Terminated	USA	0
NCT05005403	Phase I	ABBV-514 + Budigalimab ABBV-514	Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer (NSCLC), Head and Neck Squamous Cell Carcinoma (HNSCC) and Other Solid Tumors, Receiving Intravenous (IV) Infusion of ABBV-514 Alone or in Combination With Budigalimab	Recruiting	USA \| ISR	3
NCT04005144	Phase I	Binimetinib + Brigatinib	Brigatinib and Binimetinib in Treating Patients With Stage IIIB-IV ALK or ROS1-Rearranged Non-small Cell Lung Cancer	Terminated	USA	0
NCT04323436	Phase II	Capmatinib + Spartalizumab Capmatinib	Study of Capmatinib and Spartalizumab/Placebo in Advanced NSCLC Patients With MET Exon 14 Skipping Mutations	Terminated	USA \| ITA \| FRA \| ESP \| DEU \| CAN \| BEL	2
NCT03559049	Phase Ib/II	Carboplatin + Pembrolizumab + Pemetrexed Disodium + Rucaparib	Rucaparib and Pembrolizumab for Maintenance Therapy in Stage IV Non-Squamous Non-Small Cell Lung Cancer	Active, not recruiting	USA	0
NCT04614103	Phase II	LN-145	Autologous LN-145 in Patients With Metastatic Non-Small-Cell Lung Cancer	Recruiting	USA \| NLD \| DEU \| CHE \| CAN	0
NCT04625699	Phase II	Durvalumab + Tremelimumab	Study of Durvalumab + Tremelimumab in NSCLC Patients After Adjuvant Treatment	Withdrawn		0
NCT04263090	Phase Ib/II	Nivolumab + Rigosertib	Rigosertib Plus Nivolumab for KRAS+ NSCLC Patients Who Progressed on First-Line Treatment	Completed	USA	0
NCT03535740	Phase II	Brigatinib	A Study of Brigatinib in Participants With Anaplastic Lymphoma Kinase-Positive (ALK+), Advanced Non-Small-Cell Lung Cancer (NSCLC) Progressed on Alectinib or Ceritinib (ALTA-2)	Completed	USA \| SWE \| NLD \| ITA \| FRA \| ESP \| DEU \| CAN \| AUT \| AUS	5
NCT01798485	Phase III	Ganetespib Docetaxel	A Phase 3 Study of Ganetespib in Combination With Docetaxel Versus Docetaxel Alone in Patients With Advanced NSCLC	Terminated	USA \| SVN \| ROU \| POL \| NLD \| ITA \| HUN \| HRV \| GBR \| FRA \| ESP \| DEU \| CAN \| BEL \| AUT	5
NCT03665129	Phase I	Avdoralimab + Durvalumab	IPH5401 (Anti-C5aR) in Combination With Durvalumab in Patients With Advanced Solid Tumors (STELLAR-001)	Terminated	USA \| FRA	0
NCT06532032	Phase Ib/II	Amivantamab-vmjw + Docetaxel	A Study of Combination Therapy With Amivantamab and Docetaxel in Participants With Metastatic Non-small Cell Lung Cancer (swalloWTail)	Recruiting	USA \| TUR	1
NCT03664024	Phase II	Pembrolizumab + Pemetrexed Disodium Carboplatin + Pembrolizumab + Pemetrexed Disodium Cisplatin + Pembrolizumab + Pemetrexed Disodium	Biomarkers of Response to Pembrolizumab Combined With Chemotherapy in Non-Small Cell Lung Cancer (KEYNOTE-782, MK-3475-782) (KEYNOTE-782)	Completed	USA \| ISR \| HUN \| ESP \| CAN	0
NCT05785767	Phase II	Cemiplimab Cemiplimab + Fianlimab	A Study to Learn if a Combination of Fianlimab and Cemiplimab Versus Cemiplimab Alone is More Effective for Adult Participants With Advanced Non-Small Cell Lung Cancer (NSCLC)	Recruiting	USA \| TUR \| ISR \| CAN \| AUS	5
NCT04856176	Phase II	Carboplatin + Paclitaxel + Pembrolizumab + Sargramostim Carboplatin + Paclitaxel + Pembrolizumab + Pemetrexed Disodium + Sargramostim	A Study of Sargramostim Plus Pembrolizumab With or Without Pemetrexed in Patients With Advance Non-small Cell Lung Cancer After Completion of Chemoimmunotherapy	Recruiting	USA	0
NCT05948462	Phase II	Cisplatin + Lorlatinib + Pemetrexed Disodium Carboplatin + Lorlatinib + Pemetrexed Disodium	Lorlatinib in Combination With Chemotherapy in Participants With Metastatic Anaplastic Lymphoma Kinase Positive (ALK+) Non-small Cell Lung Cancer (NSCLC) Who Progressed on Single-agent Lorlatinib (NSCLC)	Withdrawn	USA	0
NCT06119581	Phase III	Cisplatin + Pembrolizumab + Pemetrexed Disodium Carboplatin + Pembrolizumab + Pemetrexed Disodium Pembrolizumab Cisplatin + LY3537982 + Pembrolizumab + Pemetrexed Disodium LY3537982 + Pembrolizumab Carboplatin + LY3537982 + Pembrolizumab + Pemetrexed Disodium	A Study of LY3537982 Plus Immunotherapy With or Without Chemotherapy in Participants With Non-Small Cell Lung Cancer (NSCLC) With a Change in a Gene Called KRAS G12C (SUNRAY-01)	Recruiting	USA \| TUR \| SWE \| ROU \| POL \| NOR \| NLD \| ITA \| HUN \| GRC \| GBR \| FRA \| ESP \| DNK \| DEU \| CZE \| CHE \| CAN \| BRA \| BEL \| AUT \| AUS	7
NCT03847519	Phase Ib/II	ADXS-503 + Pembrolizumab ADXS-503	Study of ADXS-503 With or Without Pembro in Subjects With Metastatic Non-Small Cell Lung Cancer	Completed	USA	0
NCT03786692	Phase II	Atezolizumab + Bevacizumab + Carboplatin + Pemetrexed Disodium Bevacizumab + Carboplatin + Pemetrexed Disodium	Phase II Randomized Trial of Carboplatin+Pemetrexed+Bevacizumab+/- Atezolizumab in Stage IV NSCLC	Recruiting	USA	0
NCT03371381	Phase Ib/II	JNJ-64041757 + Nivolumab Nivolumab	An Efficacy and Safety Study of JNJ-64041757, a Live Attenuated Listeria Monocytogenes Immunotherapy, in Combination With Nivolumab Versus Nivolumab Monotherapy in Participants With Advanced Adenocarcinoma of the Lung	Terminated	USA \| ESP \| BEL	0
NCT03838159	Phase II	Carboplatin + Nivolumab + Paclitaxel Carboplatin + Paclitaxel	NADIM II: Neo-Adjuvant Immunotherapy (NADIMII)	Active, not recruiting	ESP	0
NCT02513667	Phase II	Ceritinib	Ceritinib in Combination With Stereotactic Ablative Radiation Metastatic Lung Adenocarcinoma	Terminated	USA	0
NCT02733250	Phase Ib/II	Nab-paclitaxel + Pembrolizumab	Pembrolizumab With Nab-Paclitaxel in Non-Small Cell Lung Cancer (URCOH-PMS-001)	Completed	CAN	0
NCT04526691	Phase I	Cisplatin + Datopotamab deruxtecan + Pembrolizumab Carboplatin + Datopotamab deruxtecan + Pembrolizumab Datopotamab deruxtecan + Pembrolizumab	Datopotamab Deruxtecan (Dato-DXd) in Combination With Pembrolizumab With or Without Platinum Chemotherapy in Subjects With Advanced or Metastatic Non-Small Cell Lung Cancer (TROPION-Lung02)	Active, not recruiting	USA \| ITA \| ESP	2
NCT05064280	Phase II	Lenvatinib Pembrolizumab	Phase II Study of Pembrolizumab in Combination With Lenvatinib in Patients With TNBC, NSCLC, and Other Tumor Types and Brain Metastases	Recruiting	USA	0
NCT02595944	Phase III	Nivolumab	Nivolumab After Surgery and Chemotherapy in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer (An ALCHEMIST Treatment Trial) (ANVIL)	Active, not recruiting	USA	0
NCT02927340	Phase II	Lorlatinib	A Study of Lorlatinib in Advanced ALK and ROS1 Rearranged Lung Cancer With CNS Metastasis in the Absence of Measurable Extracranial Lesions	Unknown status	USA	0
NCT06472076	Phase III	Pembrolizumab Dostarlimab-gxly + EOS-448	A Study of Belrestotug Plus Dostarlimab Compared With Placebo Plus Pembrolizumab in Previously Untreated Participants With Programmed Death Ligand 1 (PD-L1) High Non-small-cell Lung Cancer (NSCLC)	Recruiting	TUR \| SWE \| SVN \| SVK \| ROU \| POL \| NLD \| ITA \| HUN \| HRV \| GRC \| FRA \| FIN \| EST \| ESP \| DEU \| CZE \| CAN \| BRA \| BGR \| BEL \| ARG	12
NCT06635824	Phase III	Docetaxel GEN1046 + Pembrolizumab	Trial to Evaluate Acasunlimab and Pembrolizumab Combination Superiority Over Standard of Care Docetaxel in Non-Small Cell Lung Cancer (ABBIL1TY NSCLC-06)	Recruiting	USA	0
NCT04499053	Phase II	Cisplatin + Durvalumab + Pemetrexed Disodium + Tremelimumab Carboplatin + Durvalumab + Nab-paclitaxel + Tremelimumab Carboplatin + Durvalumab + Pemetrexed Disodium + Tremelimumab Carboplatin + Durvalumab + Paclitaxel + Tremelimumab	Durvalumab and Tremelimumab in Combination With Chemotherapy in Virus-infected Patients With Non-small Cell Lung Cancer	Recruiting	USA	0
NCT03286296	Phase I	LZM009	LZM009 to Treat Patients With Advanced Solid Tumors	Completed	USA	0
NCT05899608	Phase III	Pembrolizumab Ivonescimab	Clinical Study of Ivonescimab for First-line Treatment of Metastatic Squamous NSCLC Patients	Recruiting	USA \| CAN	0
NCT04267848	Phase III	Cisplatin + Pembrolizumab + Pemetrexed Disodium Cisplatin + Gemcitabine Carboplatin + Pemetrexed Disodium Cisplatin + Pemetrexed Disodium Cisplatin + Gemcitabine + Pembrolizumab Carboplatin + Paclitaxel Carboplatin + Pembrolizumab + Pemetrexed Disodium Pembrolizumab Carboplatin + Paclitaxel + Pembrolizumab	Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-Small Cell Lung Cancer, ALCHEMIST Trial	Recruiting	USA	1
NCT04793815	FDA approved	Pembrolizumab	Lung Cancer Cryo-Activation as a Novel Approach to Augment Immunotherapy Efficacy (CRYOVATE)	Completed	CAN	0
NCT03131206	Phase Ib/II	Alectinib	A Study of Alectinib in RET-rearranged Non-small Cell Lung Cancer or RET-mutated Thyroid Cancer	Terminated	USA	0
NCT00585195	Phase I	Crizotinib + Itraconazole Crizotinib + Rifampin	A Study Of Oral PF-02341066, A C-Met/Hepatocyte Growth Factor Tyrosine Kinase Inhibitor, In Patients With Advanced Cancer (PROFILE 1001)	Completed	USA \| AUS	2
NCT04862780	Phase Ib/II	BLU-945 BLU-945 + Osimertinib	(SYMPHONY) Phase 1/2 Study Targeting EGFR Resistance Mechanisms in NSCLC	Active, not recruiting	USA \| NLD \| GBR \| FRA \| ESP \| CAN	4
NCT03275597	Phase I	Durvalumab + Tremelimumab	Phase Ib Study of Stereotactic Body Radiotherapy (SBRT) in Oligometastatic Non-small Lung Cancer (NSCLC) With Dual Immune Checkpoint Inhibition	Terminated	USA	0
NCT02142738	Phase III	Cisplatin Paclitaxel Carboplatin Gemcitabine Pembrolizumab Pemetrexed Disodium	Study of Pembrolizumab (MK-3475) Compared to Platinum-Based Chemotherapies in Participants With Metastatic Non-Small Cell Lung Cancer (MK-3475-024/KEYNOTE-024)	Completed		0
NCT04140500	Phase I	RO7247669	Dose Escalation Study of a PD1-LAG3 Bispecific Antibody in Patients With Advanced and/or Metastatic Solid Tumors	Active, not recruiting	TUR \| ISR \| GBR \| ESP \| DNK	5
NCT03313778	Phase I	mRNA-4157 + Pembrolizumab mRNA-4157	Safety, Tolerability, and Immunogenicity of mRNA-4157 Alone and in Combination in Participants With Solid Tumors (KEYNOTE-603)	Recruiting	USA \| GBR \| AUS	1
NCT03829319	Phase III	Carboplatin + Lenvatinib + Pembrolizumab + Pemetrexed Disodium Carboplatin + Pembrolizumab + Pemetrexed Disodium Cisplatin + Lenvatinib + Pembrolizumab + Pemetrexed Disodium Cisplatin + Pembrolizumab + Pemetrexed Disodium	Safety and Efficacy Study of Pemetrexed + Platinum Chemotherapy + Pembrolizumab (MK-3475) With or Without Lenvatinib (MK-7902/E7080) as First-line Intervention in Adults With Metastatic Nonsquamous Non-small Cell Lung Cancer (MK-7902-006/E7080-G000-315/LEAP-006)	Active, not recruiting	USA \| TUR \| POL \| NZL \| ISR \| GBR \| FRA \| ESP \| DEU \| CAN \| AUS \| ARG	5
NCT03093116	Phase Ib/II	Repotrectinib	A Study of Repotrectinib (TPX-0005) in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements (TRIDENT-1)	Recruiting	USA \| POL \| NLD \| ITA \| HUN \| GBR \| FRA \| ESP \| DNK \| DEU \| CAN \| BEL \| AUS	6
NCT03308942	Phase II	Niraparib Niraparib + Pembrolizumab Dostarlimab-gxly + Niraparib	Effects of Single Agent Niraparib and Niraparib Plus Programmed Cell Death-1 (PD-1) Inhibitors in Non-Small Cell Lung Cancer Participants	Completed	USA	0
NCT05012254	Phase II	Ipilimumab + Nivolumab Carboplatin + Ipilimumab + Nivolumab + Paclitaxel Cisplatin + Ipilimumab + Nivolumab + Pemetrexed Disodium Carboplatin + Ipilimumab + Nivolumab + Pemetrexed Disodium	Nivolumab and Ipilimumab Plus Chemotherapy for Patients With Stage IV Lung Cancer With Brain Metastases (NIVIPI-Brain)	Active, not recruiting	ESP	0
NCT06074588	Phase III	Docetaxel SKB264 Pemetrexed Disodium	Sacituzumab Tirumotecan (MK-2870) Versus Chemotherapy in Previously Treated Advanced or Metastatic Nonsquamous Non-small Cell Lung Cancer (NSCLC) With EGFR Mutations or Other Genomic Alterations (MK-2870-004)	Recruiting	USA \| TUR \| POL \| ITA \| ISR \| GRC \| GBR \| FRA \| ESP \| DEU \| CZE \| CAN \| BRA \| AUS	10
NCT05882734	Phase Ib/II	Cemiplimab + M1774	Tuvusertib (M1774) in Combination With Cemiplimab in Participants With Non-Squamous NSCLC (DDRiver NSCLC 322)	Active, not recruiting	USA \| ITA \| FRA \| ESP \| DEU \| BEL	2
NCT02227940	Phase I	Ceritinib + Gemcitabine + Nab-paclitaxel Ceritinib + Cisplatin + Gemcitabine Ceritinib + Gemcitabine	Ceritinib and Combination Chemotherapy in Treating Patients With Advanced Solid Tumors or Locally Advanced or Metastatic Pancreatic Cancer	Completed	USA	0
NCT05317858	Phase III	Pembrolizumab	Blood-brain Barrier (BBB) Disruption Using Exablate Focused Ultrasound With Standard of Care Treatment of NSCLC Brain Mets	Recruiting	USA \| CAN	1
NCT03417037	Phase III	Linrodostat + Nivolumab	An Immuno-Therapy Study of Experimental Medication BMS-986205 Given With Nivolumab With or Without Chemotherapy Compared to Chemotherapy in Participants With Previously Untreated Stage IV or Recurrent Non-Small Cell Lung Cancer	Withdrawn	USA \| TUR \| ITA \| GRC \| FRA \| ESP \| DEU \| CZE \| CHE \| CAN \| BRA \| AUT \| AUS	4
NCT02654587	Phase III	OSE 2101 Pemetrexed Disodium Docetaxel	Study of OSE2101 Versus Standard Treatment as 2nd or 3rd Line in HLA-A2 Positive Patients With Advanced NSCLC After Failure of Immune Checkpoint Inhibitor (ATALANTE 1)	Terminated	USA \| POL \| ITA \| ISR \| HUN \| GBR \| FRA \| ESP \| DEU \| CZE	0
NCT02864992	Phase II	Tepotinib	Tepotinib Phase II in NSCLC Harboring MET Alterations (VISION)	Active, not recruiting	USA \| POL \| NLD \| ITA \| ISR \| FRA \| ESP \| DEU \| CHE \| BEL \| AUT	4
NCT04262375	Phase II	Durvalumab + Oleclumab	A Phase 2 Study of Durvalumab (MEDI4736) and Oleclumab (MEDI9447) in Multi-Cancer Populations With Correlation to Clinical, Molecular and Immunologic Parameters With DNA MethylaTION (DOMINATION)	Withdrawn	CAN	0
NCT05631574	Phase I	BMF-219	Study of Covalent Menin Inhibitor BMF-219 in Adult Patients With KRAS Driven Non-Small Cell Lung Cancer, Pancreatic Cancer, and Colorectal Cancer	Recruiting	USA	1
NCT03166631	Phase I	BI 891065 + Ezabenlimab BI 891065	A Trial to Find the Safe Dose for BI 891065 Alone and in Combination With BI 754091 in Patients With Incurable Tumours or Tumours That Have Spread	Terminated	USA	0
NCT02521051	Phase Ib/II	Bevacizumab Alectinib	Phase I/II Trial of Alectinib and Bevacizumab in Patients With Advanced, Anaplastic Lymphoma Kinase (ALK)-Positive, Non-Small Cell Lung Cancer	Unknown status	USA	0
NCT05836324	Phase I	INCA33890	A Study to Evaluate the Safety of INCA33890 in Participants With Advanced or Metastatic Solid Tumors	Recruiting	USA \| ITA \| GBR \| FRA \| ESP \| DNK \| CHE	0
NCT04639245	Phase Ib/II	MAGE-A1-specific TCR cells + unspecified PD-1 antibody Cyclophosphamide + Fludarabine Atezolizumab + MAGE-A1-specific TCR cells MAGE-A1-specific TCR cells	Genetically Engineered Cells (MAGE-A1-specific T Cell Receptor-transduced Autologous T-cells) and Atezolizumab for the Treatment of Metastatic Triple Negative Breast Cancer, Urothelial Cancer, or Non-small Cell Lung Cancer	Terminated	USA	0
NCT03202940	Phase Ib/II	Alectinib + Cobimetinib	A Phase IB/II Study of Alectinib Combined With Cobimetinib in Advanced ALK-Rearranged (ALK+) NSCLC	Active, not recruiting	USA	0
NCT06161441	Phase II	Carboplatin + Cemiplimab + Pemetrexed Disodium Carboplatin + Cemiplimab + Paclitaxel Cemiplimab + Fianlimab Cemiplimab + Cisplatin + Paclitaxel Cemiplimab + Cisplatin + Pemetrexed Disodium Cemiplimab + Cisplatin + Fianlimab + Pemetrexed Disodium Carboplatin + Cemiplimab + Fianlimab + Pemetrexed Disodium Carboplatin + Cemiplimab + Fianlimab + Paclitaxel Cemiplimab + Cisplatin + Fianlimab + Paclitaxel	A Trial to Learn if the Combination of Fianlimab, Cemiplimab, and Chemotherapy is Safe and Works Better Than the Combination of Cemiplimab and Chemotherapy in Adult Patients With Non-Small Cell Lung Cancer That Can be Treated With Surgery	Recruiting	USA \| AUS	2
NCT04033354	Phase III	Carboplatin + Nab-paclitaxel + Serplulimab Carboplatin + Nab-paclitaxel	A Randomized, Double-blind, Placebo Controlled Phase III Study to Investigate Efficacy and Safety of First-Line Treatment With HLX10 + Chemotherapy (Carboplatin-Nanoparticle Albumin Bound (Nab) Paclitaxel) in Patients With Stage IIIB/IIIC or IV NSCLC	Active, not recruiting	USA \| TUR \| POL	4
NCT06522360	Phase II	Brigatinib Brigatinib + Carboplatin + Pemetrexed Disodium	Brigatinib Plus Chemotherapy or Local Consolidation Therapy in ALK Positive Advanced Non-small Cell Lung Cancer (BrightStar-2)	Not yet recruiting	USA	0
NCT04811001	Phase II	Dacomitinib Osimertinib	Best EGFR-TKI Sequence in NSCLC Harboring EGFR Mutations (CAPLAND)	Recruiting	ITA	0
NCT02848651	Phase II	Atezolizumab	A Study of Atezolizumab (MPDL3280A) as First-line Monotherapy for Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC): Clinical Evaluation of Novel Blood-Based Diagnostics [B-F1RST]	Completed	USA	0
NCT03707938	Phase I	Brigatinib	Local Consolidative Therapy and Brigatinib in Treating Patients With Stage IV or Recurrent Non-small Cell Lung Cancer	Active, not recruiting	USA	0
NCT04895579	Phase I	Copanlisib + Durvalumab	Lung Cancer With Copanlisib and Durvalumab (LCD)	Active, not recruiting	USA	0
NCT03596866	Phase III	Brigatinib Alectinib	A Study of Brigatinib Compared to Alectinib in Adults With Non-Small-Cell Lung Cancer (ALTA-3)	Completed	USA \| SWE \| ROU \| ITA \| HRV \| GRC \| FRA \| ESP \| DEU \| CAN \| AUT \| ARG	8
NCT03322566	Phase II	Carboplatin + Paclitaxel + Pembrolizumab Epacadostat + Pembrolizumab Carboplatin + Pembrolizumab + Pemetrexed Disodium Pemetrexed Disodium Carboplatin + Epacadostat + Pembrolizumab + Pemetrexed Disodium Cisplatin + Pembrolizumab + Pemetrexed Disodium Carboplatin + Epacadostat + Paclitaxel + Pembrolizumab Cisplatin + Epacadostat + Pembrolizumab + Pemetrexed Disodium	A Study of Pembrolizumab Plus Epacadostat With Platinum-based Chemotherapy Versus Pembrolizumab Plus Platinum-based Chemotherapy Plus Placebo in Metastatic Non-Small Cell Lung Cancer (KEYNOTE-715-06/ECHO-306-06)	Completed	USA \| TUR \| ITA \| ISR \| IRL \| HUN \| GBR \| ESP \| CAN \| AUS	4
NCT04362072	FDA approved	Lorlatinib	Study of Lorlatinib In People With ALK-positive Non-small Cell Lung Cancer	Completed	USA \| POL \| ITA \| GBR \| ESP \| CHE	1
NCT06472245	Phase III	OSE 2101 Docetaxel	Trial of Therapeutic Cancer Vaccine OSE2101 in Patients With Non-Small Cell Lung Cancer and Secondary Resistance to Immune Checkpoint Inhibitor (ARTEMIA)	Not yet recruiting	USA	0
NCT04547504	Phase III	Cisplatin + Pembrolizumab + Pemetrexed Disodium Pemetrexed Disodium Pembrolizumab Carboplatin + Paclitaxel + Pembrolizumab Carboplatin + Pembrolizumab + Pemetrexed Disodium Pembrolizumab + Pemetrexed Disodium	PEmbRolizumab verSus chEmotherapy and pEmbrolizumab in Non-small-cell Lung Cancers (NSCLC) With PDL1 >= 50 % (PERSEE)	Active, not recruiting	FRA	0
NCT05007769	Phase II	Atezolizumab + Nogapendekin alfa inbakicept + Ramucirumab	Ramucirumab, Atezolizumab and N-803 After Progression on Any Immune Checkpoint Blocker in NSCLC (RAN)	Withdrawn		0
NCT05597800	Phase II	Carboplatin + Ipilimumab + Nivolumab + Pemetrexed Disodium Cisplatin + Ipilimumab + Nivolumab + Pemetrexed Disodium Carboplatin + Ipilimumab + Nivolumab + Paclitaxel	Nivolumab/Ipilimumab and Chemotherapy Combination in Advanced NSCLC Patients With HIV, HBV, HCV and Long Covid Syndrome (LUNGVIR)	Not yet recruiting	ITA	0
NCT06331455	Phase II	Durvalumab	Treatment of Pulmonary SUlcus, Pancoast and Chest Wall Non-small Cell Lung Cancer Employing Radiation, Immuno-oncology and Resection (SUPER)	Recruiting	CAN	0
NCT02292550	Phase Ib/II	Ceritinib + Ribociclib	Study of Safety and Efficacy of LEE011 and Ceritinib in Patients With ALK-positive Non-small Cell Lung Cancer.	Completed	USA \| ITA \| FRA \| ESP	2
NCT04467723	Phase Ib/II	Atezolizumab + Pirfenidone	Combination of Atezolizumab and Pirfenidone in Second-line and Beyond NSCLC	Recruiting	USA	0
NCT03526887	Phase II	Pembrolizumab	Re-challenge Pembrolizumab Study as a Second or Further Line in Patients With Advanced NSCLC (Replay)	Completed	ESP	0
NCT01772797	Phase I	Ceritinib Luminespib	Phase Ib Study of LDK378 and AUY922 in ALK-rearranged Non-small Cell Lung Cancer	Completed	USA \| ITA \| ESP \| AUS	1
NCT05676749	Phase I	Aldesleukin + C-TIL051 + Pembrolizumab	C-TIL051 in Non-Small Cell Lung Cancer	Recruiting	USA	0
NCT05633667	Phase II	Etrumadenant + Sacituzumab govitecan-hziy + Zimberelimab Carboplatin + Paclitaxel + Zimberelimab Carboplatin + Nab-paclitaxel + Zimberelimab Docetaxel Etrumadenant + Zimberelimab Cisplatin + Pemetrexed Disodium + Zimberelimab Carboplatin + Pemetrexed Disodium + Zimberelimab AB154 + Sacituzumab govitecan-hziy + Zimberelimab AB154 + Etrumadenant + Zimberelimab Sacituzumab govitecan-hziy	Study of Novel Treatment Combinations in Patients With Lung Cancer (VELOCITY-Lung)	Recruiting	USA \| ISR \| GBR \| BRA	3
NCT04984811	Phase II	Atezolizumab + NT-I7	NT-I7 in Combination With Atezolizumab in Previously Untreated, PD-L1-expressing, Locally Advanced or Metastatic NSCLC	Active, not recruiting	USA	0
NCT03194893	Phase III	Crizotinib Alectinib	A Rollover Study of Alectinib in Patients With Anaplastic Lymphoma Kinase (ALK)-Positive or Rearranged During Transfection (RET)-Positive Cancer	Recruiting	USA \| TUR \| POL \| ITA \| FRA \| ESP	4
NCT03827850	Phase II	Erdafitinib	FGFR Inhibitor in FGFR Dysregulated Cancer (FIND)	Terminated	DEU	0
NCT01579994	Phase I	Crizotinib + Ganetespib	Crizotinib and Ganetespib (STA-9090) in ALK Positive Lung Cancers	Completed	USA	0
NCT04139317	Phase II	Capmatinib + Pembrolizumab Pembrolizumab	Safety and Efficacy of Capmatinib (INC280) Plus Pembrolizumab vs Pembrolizumab Alone in NSCLC With PD-L1 >= 50%	Terminated	NLD \| ITA \| GRC \| FRA \| ESP \| DEU \| CZE \| CAN \| BEL \| AUS	6
NCT05014815	Phase II	BGBA1217 + Tislelizumab Tislelizumab	Ociperlimab With Tislelizumab and Chemotherapy in Participants With Untreated Metastatic Non-Small Cell Lung Cancer	Completed	USA \| FRA \| ESP \| AUT \| AUS	2
NCT05159245	Phase II	Vemurafenib Tepotinib Vismodegib Apalutamide Alectinib Regorafenib Entrectinib Pertuzumab + Trastuzumab Pemigatinib Atezolizumab Cobimetinib Dabrafenib + Trametinib Dabrafenib Trametinib Abemaciclib	The Finnish National Study to Facilitate Patient Access to Targeted Anti-cancer Drugs (FINPROVE)	Recruiting	FIN	0
NCT05015010	Phase II	Alectinib	Alectinib in Neo-adjuvant Treatment of Stage III NSCLC (ALNEO)	Active, not recruiting	ITA	0
NCT04956692	Phase III	Cisplatin + Pembrolizumab + Pemetrexed Disodium Carboplatin + Pembrolizumab + Pemetrexed Disodium Carboplatin + Paclitaxel + Pembrolizumab Carboplatin + Nab-paclitaxel + Pembrolizumab	Study of Pembrolizumab (MK-3475) Subcutaneous (SC) Versus Pembrolizumab Intravenous (IV) Administered With Platinum Doublet Chemotherapy in Participants With Metastatic Squamous or Nonsquamous Non-Small Cell Lung Cancer (NSCLC) (MK-3475-A86)	Active, not recruiting	USA \| TUR \| ROU \| POL \| HUN \| FRA \| ESP \| BRA	8
NCT03164772	Phase Ib/II	BI 1361849 + Durvalumab + Tremelimumab	Phase 1/2 Study of Combination Immunotherapy and mRNA Vaccine in Subjects With NSCLC	Completed	USA	0
NCT03302234	Phase III	Pembrolizumab Ipilimumab + Pembrolizumab	Study of Pembrolizumab Given With Ipilimumab or Placebo in Participants With Untreated Metastatic Non-small Cell Lung Cancer (MK-3475-598/KEYNOTE-598)	Completed	USA \| TUR \| POL \| LVA \| ITA \| IRL \| HUN \| GBR \| FRA \| ESP \| DEU \| CAN \| BRA \| AUS \| ARG	9
NCT05858164	Phase I	BAY2862789	A First-in-human Study to Learn How Safe the Study Treatment BAY2862789 is, to Find the Best Dose, How it Affects the Body, What Maximum Amount Can be Given, How it Moves Into, Through and Out of the Body, and How it Acts on Different Tumors in Participants With Advanced Solid Tumors	Recruiting	USA \| ISR \| ESP \| AUS	3
NCT06431633	Phase II	Zimberelimab Cisplatin Sacituzumab govitecan-hziy + Zimberelimab Carboplatin	Study of Treatment With Sacituzumab and Zimberelimab for Patients With Lung Cancer Confined to the Chest and Previously Operated on Who Were Not Disease-free. (ARIAN)	Not yet recruiting	ESP	0
NCT03023904	Phase II	Nivolumab	Nivolumab in Treating Patients With Stage IV or Recurrent Lung Cancer With High Mutation Loads	Withdrawn		0
NCT03708328	Phase I	RO7121661	A Dose Escalation and Expansion Study of Lomvastomig, a PD-1/TIM-3 Bispecific Antibody, in Participants With Advanced and/or Metastatic Solid Tumors	Completed	USA \| NZL \| FRA \| ESP \| DNK	1
NCT04758949	Phase II	Nivolumab FL-101 + Nivolumab FL-101	FL-101 in Surgically Resectable Non-Small Cell Lung Cancer	Withdrawn		0
NCT01803282	Phase I	Andecaliximab Fluorouracil + Leucovorin + Oxaliplatin + Pembrolizumab Carboplatin + Pemetrexed Disodium Fluorouracil + Irinotecan + Leucovorin Gemcitabine + Nab-paclitaxel Carboplatin + Paclitaxel Paclitaxel Bevacizumab	Safety and Tolerability Study in Solid Tumors	Completed	USA	0
NCT05840770	Phase II	Cemiplimab	Cemiplimab for the Treatment of Untreated Brain Metastases From PD-L1 >= 50% Non-Small Cell Lung Cancer	Recruiting	USA	0
NCT02706626	Phase II	Brigatinib	Trial of Brigatinib After Treatment With Next-Generation ALK Inhibitors	Terminated	USA	0
NCT05568212	Phase II	Durvalumab Durvalumab + Olaparib	Randomized Trial Comparing Standard of Care Versus Immune- Based Combination in Relapsed Stage III Non-small-cell Lung Cancer (NSCLC) Pretreated With Chemoradiotherapy and Durvalumab	Recruiting	ITA	0
NCT05777603	Phase I	Aztreonam + Pembrolizumab + Vancomycin	Study of Aerosolized Antibiotics and Pembrolizumab in Advanced Non-small Cell Lung Cancer	Recruiting	USA	0
NCT03631706	Phase II	Bintrafusp alfa Pembrolizumab	M7824 Versus Pembrolizumab as a First-line (1L) Treatment in Participants With Programmed Death-ligand 1 (PD-L1) Expressing Advanced Non-small Cell Lung Cancer (NSCLC)	Completed	USA \| TUR \| NLD \| ITA \| GRC \| FRA \| ESP \| DEU \| CAN \| BRA \| BEL \| ARG	6
NCT03348904	Phase III	Carboplatin + Cisplatin + Gemcitabine + Nivolumab + Paclitaxel + Pemetrexed Disodium Carboplatin + Cisplatin + Gemcitabine + Paclitaxel + Pemetrexed Disodium Carboplatin + Cisplatin + Epacadostat + Gemcitabine + Nivolumab + Paclitaxel + Pemetrexed Disodium	Nivolumab and Epacadostat With Platinum Doublet Chemotherapy Versus Platinum Doublet Chemotherapy in Non-Small Cell Lung Cancer	Terminated	USA	0
NCT05687266	Phase III	Carboplatin + Pembrolizumab + Pemetrexed Disodium Carboplatin + Paclitaxel + Pembrolizumab Carboplatin + Datopotamab deruxtecan + Durvalumab Cisplatin + Pembrolizumab + Pemetrexed Disodium	Phase III, Open-label, First-line Study of Dato-DXd in Combination With Durvalumab and Carboplatin for Advanced NSCLC Without Actionable Genomic Alterations (AVANZAR)	Recruiting	USA \| TUR \| SWE \| POL \| ITA \| HUN \| GRC \| GBR \| FRA \| ESP \| DNK \| DEU \| CAN \| BRA \| BGR \| AUT	8
NCT02414139	Phase II	Capmatinib	Clinical Study of Oral cMET Inhibitor INC280 in Adult Patients With EGFR Wild-type Advanced Non-small Cell Lung Cancer (Geometry Mono-1)	Completed	USA \| SWE \| NOR \| NLD \| LBN \| ITA \| ISR \| GBR \| FRA \| ESP \| DEU \| BEL \| AUT \| ARG	6
NCT03456076	Phase III	Cisplatin Alectinib Carboplatin Gemcitabine Pemetrexed Disodium Vinorelbine	A Study Comparing Adjuvant Alectinib Versus Adjuvant Platinum-Based Chemotherapy in Patients With ALK Positive Non-Small Cell Lung Cancer	Active, not recruiting	USA \| TUR \| ROU \| POL \| ITA \| ISR \| HUN \| GRC \| GBR \| FRA \| ESP \| DNK \| DEU \| AUT \| AUS	12
NCT03220477	Phase I	Guadecitabine + Mocetinostat + Pembrolizumab	Pembrolizumab (Immunotherapy Drug) in Combination With Guadecitabine and Mocetinostat (Epigenetic Drugs) for Patients With Advanced Lung Cancer.	Active, not recruiting	USA	0
NCT03737994	Phase II	Cisplatin + Lorlatinib Carboplatin + Lorlatinib Ceritinib Alectinib + Cisplatin Alectinib + Carboplatin Ceritinib + Cisplatin Pemetrexed Disodium Carboplatin + Ceritinib Cisplatin + Ensartinib Carboplatin + Ensartinib Brigatinib + Cisplatin Brigatinib Alectinib Brigatinib + Carboplatin Ensartinib Cisplatin + Pemetrexed Disodium Crizotinib Carboplatin + Pemetrexed Disodium Lorlatinib	Targeted Treatment for ALK Positive Patients Who Have Previously Been Treated for Non-squamous Non-small Cell Lung Cancer	Active, not recruiting	USA	0
NCT04223596	Phase II	Brigatinib	Clinical Utility of Liquid Biopsy in Brigatinib ALK+ Patients (CUBIK)	Active, not recruiting	ESP	0
NCT02094573	Phase II	Brigatinib	A Phase 2, Multicenter, Randomized Study of AP26113	Completed		0
NCT03737994	Phase II	Cisplatin + Lorlatinib Carboplatin + Lorlatinib Ceritinib Alectinib + Cisplatin Alectinib + Carboplatin Ceritinib + Cisplatin Pemetrexed Disodium Carboplatin + Ceritinib Cisplatin + Ensartinib Carboplatin + Ensartinib Brigatinib + Cisplatin Brigatinib Alectinib Brigatinib + Carboplatin Ensartinib Cisplatin + Pemetrexed Disodium Crizotinib Carboplatin + Pemetrexed Disodium Lorlatinib	Targeted Treatment for ALK Positive Patients Who Have Previously Been Treated for Non-squamous Non-small Cell Lung Cancer	Active, not recruiting	USA	0
NCT03737994	Phase II	Cisplatin + Lorlatinib Carboplatin + Lorlatinib Ceritinib Alectinib + Cisplatin Alectinib + Carboplatin Ceritinib + Cisplatin Pemetrexed Disodium Carboplatin + Ceritinib Cisplatin + Ensartinib Carboplatin + Ensartinib Brigatinib + Cisplatin Brigatinib Alectinib Brigatinib + Carboplatin Ensartinib Cisplatin + Pemetrexed Disodium Crizotinib Carboplatin + Pemetrexed Disodium Lorlatinib	Targeted Treatment for ALK Positive Patients Who Have Previously Been Treated for Non-squamous Non-small Cell Lung Cancer	Active, not recruiting	USA	0
NCT03737994	Phase II	Cisplatin + Lorlatinib Carboplatin + Lorlatinib Ceritinib Alectinib + Cisplatin Alectinib + Carboplatin Ceritinib + Cisplatin Pemetrexed Disodium Carboplatin + Ceritinib Cisplatin + Ensartinib Carboplatin + Ensartinib Brigatinib + Cisplatin Brigatinib Alectinib Brigatinib + Carboplatin Ensartinib Cisplatin + Pemetrexed Disodium Crizotinib Carboplatin + Pemetrexed Disodium Lorlatinib	Targeted Treatment for ALK Positive Patients Who Have Previously Been Treated for Non-squamous Non-small Cell Lung Cancer	Active, not recruiting	USA	0
NCT03737994	Phase II	Cisplatin + Lorlatinib Carboplatin + Lorlatinib Ceritinib Alectinib + Cisplatin Alectinib + Carboplatin Ceritinib + Cisplatin Pemetrexed Disodium Carboplatin + Ceritinib Cisplatin + Ensartinib Carboplatin + Ensartinib Brigatinib + Cisplatin Brigatinib Alectinib Brigatinib + Carboplatin Ensartinib Cisplatin + Pemetrexed Disodium Crizotinib Carboplatin + Pemetrexed Disodium Lorlatinib	Targeted Treatment for ALK Positive Patients Who Have Previously Been Treated for Non-squamous Non-small Cell Lung Cancer	Active, not recruiting	USA	0
NCT03737994	Phase II	Cisplatin + Lorlatinib Carboplatin + Lorlatinib Ceritinib Alectinib + Cisplatin Alectinib + Carboplatin Ceritinib + Cisplatin Pemetrexed Disodium Carboplatin + Ceritinib Cisplatin + Ensartinib Carboplatin + Ensartinib Brigatinib + Cisplatin Brigatinib Alectinib Brigatinib + Carboplatin Ensartinib Cisplatin + Pemetrexed Disodium Crizotinib Carboplatin + Pemetrexed Disodium Lorlatinib	Targeted Treatment for ALK Positive Patients Who Have Previously Been Treated for Non-squamous Non-small Cell Lung Cancer	Active, not recruiting	USA	0
NCT03737994	Phase II	Cisplatin + Lorlatinib Carboplatin + Lorlatinib Ceritinib Alectinib + Cisplatin Alectinib + Carboplatin Ceritinib + Cisplatin Pemetrexed Disodium Carboplatin + Ceritinib Cisplatin + Ensartinib Carboplatin + Ensartinib Brigatinib + Cisplatin Brigatinib Alectinib Brigatinib + Carboplatin Ensartinib Cisplatin + Pemetrexed Disodium Crizotinib Carboplatin + Pemetrexed Disodium Lorlatinib	Targeted Treatment for ALK Positive Patients Who Have Previously Been Treated for Non-squamous Non-small Cell Lung Cancer	Active, not recruiting	USA	0
NCT03737994	Phase II	Cisplatin + Lorlatinib Carboplatin + Lorlatinib Ceritinib Alectinib + Cisplatin Alectinib + Carboplatin Ceritinib + Cisplatin Pemetrexed Disodium Carboplatin + Ceritinib Cisplatin + Ensartinib Carboplatin + Ensartinib Brigatinib + Cisplatin Brigatinib Alectinib Brigatinib + Carboplatin Ensartinib Cisplatin + Pemetrexed Disodium Crizotinib Carboplatin + Pemetrexed Disodium Lorlatinib	Targeted Treatment for ALK Positive Patients Who Have Previously Been Treated for Non-squamous Non-small Cell Lung Cancer	Active, not recruiting	USA	0
NCT03737994	Phase II	Cisplatin + Lorlatinib Carboplatin + Lorlatinib Ceritinib Alectinib + Cisplatin Alectinib + Carboplatin Ceritinib + Cisplatin Pemetrexed Disodium Carboplatin + Ceritinib Cisplatin + Ensartinib Carboplatin + Ensartinib Brigatinib + Cisplatin Brigatinib Alectinib Brigatinib + Carboplatin Ensartinib Cisplatin + Pemetrexed Disodium Crizotinib Carboplatin + Pemetrexed Disodium Lorlatinib	Targeted Treatment for ALK Positive Patients Who Have Previously Been Treated for Non-squamous Non-small Cell Lung Cancer	Active, not recruiting	USA	0
NCT03737994	Phase II	Cisplatin + Lorlatinib Carboplatin + Lorlatinib Ceritinib Alectinib + Cisplatin Alectinib + Carboplatin Ceritinib + Cisplatin Pemetrexed Disodium Carboplatin + Ceritinib Cisplatin + Ensartinib Carboplatin + Ensartinib Brigatinib + Cisplatin Brigatinib Alectinib Brigatinib + Carboplatin Ensartinib Cisplatin + Pemetrexed Disodium Crizotinib Carboplatin + Pemetrexed Disodium Lorlatinib	Targeted Treatment for ALK Positive Patients Who Have Previously Been Treated for Non-squamous Non-small Cell Lung Cancer	Active, not recruiting	USA	0
NCT03737994	Phase II	Cisplatin + Lorlatinib Carboplatin + Lorlatinib Ceritinib Alectinib + Cisplatin Alectinib + Carboplatin Ceritinib + Cisplatin Pemetrexed Disodium Carboplatin + Ceritinib Cisplatin + Ensartinib Carboplatin + Ensartinib Brigatinib + Cisplatin Brigatinib Alectinib Brigatinib + Carboplatin Ensartinib Cisplatin + Pemetrexed Disodium Crizotinib Carboplatin + Pemetrexed Disodium Lorlatinib	Targeted Treatment for ALK Positive Patients Who Have Previously Been Treated for Non-squamous Non-small Cell Lung Cancer	Active, not recruiting	USA	0
NCT03737994	Phase II	Cisplatin + Lorlatinib Carboplatin + Lorlatinib Ceritinib Alectinib + Cisplatin Alectinib + Carboplatin Ceritinib + Cisplatin Pemetrexed Disodium Carboplatin + Ceritinib Cisplatin + Ensartinib Carboplatin + Ensartinib Brigatinib + Cisplatin Brigatinib Alectinib Brigatinib + Carboplatin Ensartinib Cisplatin + Pemetrexed Disodium Crizotinib Carboplatin + Pemetrexed Disodium Lorlatinib	Targeted Treatment for ALK Positive Patients Who Have Previously Been Treated for Non-squamous Non-small Cell Lung Cancer	Active, not recruiting	USA	0

Gene	ALK
Variant	rearrange
Impact List	unknown
Protein Effect	unknown
Gene Variant Descriptions	ALK rearrangement indicates an unspecified rearrangement of the ALK gene.
Associated Drug Resistance
Category Variants Paths	ALK mutant ALK rearrange

Gene Variant Detail

Contact

Filtering

Sorting

Filtering

Sorting